FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Australia Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
			•	MK	The former Yugoslav	TM	Turkmenistan
BE	Belgium	GN	Guinea	IVIK	_	TR	Turkey
BF	Burkina Faso	GR	Greece		Republic of Macedonia		•
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	Œ	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

1

A METHOD IN QUALITY CONTROL OF A SPECTROPHOTOMETER

FIELD OF THE INVENTION

The present invention relates to a method in quality control of a spectrophotometer for monitoring performance of the spectrophotometer, such as an oximeter for measurement of blood parameters.

10 BACKGROUND OF THE INVENTION

Spectrophotometers for measuring the composition of a substance by absorption spectroscopy are well known. For example, oximeters are used to determine

- concentrations of various hemoglobin components or fractions in blood samples from measuring an absorption spectrum in the visible and/or infrared wavelength range. Such an oximeter is disclosed in EP 210417.
- In absorption spectroscopy, determination of a spectrum of a fluid sample is performed by transmission of light through a cuvette containing a part of the sample.
- Absorption spectroscopy is based on Lambert-Beer's law according to which the absorbance determined for a sample containing a single optically active component (a dye) is directly proportional to the concentration of the component and the length of the light path through the sample in the cuvette:

30 $A(\lambda) = \varepsilon(\lambda) c d \tag{1}$

in which

35 $A(\lambda)$ is the determined absorbance at wavelength λ ,

25

- $\epsilon(\lambda)$ is the molar extinction coefficient for the component at wavelength $\lambda,$
- 5 c is the molar concentration of the component, and

d is the length of the light path through the cuvette holding the sample.

10 The absorbance $A(\lambda)$ of the sample is defined as the logarithm of the ratio of the light intensity before and after transmission through the sample. In practice the absorbance $A(\lambda)$ is defined as the logarithm of the ratio between the light intensity, I_{0} , transmitted through a transparent aqueous reference solution and the light intensity transmitted through the sample:

$$A\left(\lambda\right) = \log \frac{I_0}{T} \tag{2}$$

For samples containing more than one optically active component, the total absorbance A_{total} is the sum of the individual components' absorbances since absorbance is an additive quantity. Thus, with Y optically active components in a sample the total absorbance is given by

$$A_{total}(\lambda) = \sum_{y=1}^{Y} \varepsilon_{y}(\lambda) c_{y} d$$
 (3)

In a sample spectrum, the absorption $A_{total}(\lambda)$ recorded at each wavelength λ contains contributions from each of the components in the sample. The magnitude of this contribution and thereby the concentration of each component in the sample is determined according to

3

$$C_{y} = \sum_{j=1}^{J} K_{y}(\lambda_{j}) A_{total}(\lambda_{j})$$
 (4)

in which

- J is the total number of wavelengths λ_j at which absorption is determined by the spectrophotometer and $K_y(\lambda_j)$ is a constant specific for component y at wavelength λ_j .
- The vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$ may be determined mathematically by using methods such as multivariate analysis, or solving n equations with n unknowns, on data from reference samples.
- It is also known to monitor performance of spectrophotometers, such as oximeters, by a measuring the absorption spectrum of a fluid quality control sample, QC sample, with the spectrophotometer in question.
- Known quality control samples specific for blood analysis are typically red dye based samples designed to simulate the spectrum of blood. In addition to a red dye, they sometimes contain certain amounts of oxygen, carbon dioxide, and electrolytes at an established pH for determining performance of blood gas and electrolyte instruments. Synthetic QC samples having an absorption spectrum that closely mimics that of physiological blood have not yet been provided.
- Quality control of spectrophotometers, such as an oximeter, is typically performed by measuring the absorption spectrum of a QC sample comprising three to four different dyes. The dyes are mixed in a proportion so that the QC sample absorption spectrum mimics the ab-

4

sorption spectrum of blood. A spectrum of a QC sample is measured on the oximeter to be monitored and the parameter values determined by the oximeter are compared with predetermined control limits assigned to the QC sample by a qualified person. If the determined parameters are outside the corresponding control limits, servicing of the oximeter is required.

5

30

35

In WO 96/30742 a quality control method for monitoring performance of an oximeter is disclosed. The method comprises measuring the absorption spectrum of a QC sample and comparing it to a standard spectrum of the QC sample. Instrumental errors of the oximeter are considered to be the primary source contributing to the observed difference. Instrumental errors are converted into blood component concentration values so that instrument errors can be reported in terms understood by the operator of the instrument.

It is an important disadvantage of known quality control methods that, typically, known QC samples comprise 3-4 different dyes, causing long-term stability of the sample to be less than desired. To compensate for this, parameter value acceptance ranges in an oximeter may be widened leading to a more relaxed performance monitoring than desired.

It is another important disadvantage of known quality control methods that it is impossible with known quality control methods to distinguish between different types of instrument errors and to determine an individual contribution to deviation in parameter values from a specific type of instrument error. Thus, parameter value acceptance ranges have to be sufficiently wide to accommodate any possible type of instrument error. Fur-

WO 99/66310

5

PCT/DK99/00313

ther, a quality controlled spectrophotometer cannot be diagnosed if the determined parameter values lie outside the acceptable ranges. For example, a defect spectrophotometer with a wavelength shift may introduce the same deviation in the determined parameters as seen by dilution of the QC sample.

Future spectrophotometers are expected to facilitate determination of absorption spectra with improved resolution whereby instruments of higher precision and specificity are provided. High resolution measurements of spectra makes it more difficult to develop a suitable QC sample since precision and long term stability requirements are increased.

15

20

10

5

One of the most significant errors occurring in spectrophotometers is a wavelength shift. Due to manufacturing tolerances and drift during use, each spectrophotometer positions a determined spectrum slightly differently along the wavelength axis. Therefore the wavelengths at which absorbance is determined are also positioned slightly differently for different spectrophotometers and thus, determined absorbances will vary for different spectrophotometers.

25

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a quality control method that facilitates the determination of various types of spectrophotometers errors, whereby an accurate diagnosis of an instrument failing the QC test is provided.

6

An instrument error affects the spectrum of a sample, and specific types of instrument errors affect the spectrum in a distinct way that may be interpreted like the presence of a component in the sample in a different concentration. For example, a variation of the length d of the light path through the cuvette causes determined absorbances $A(\lambda)$ to vary according to Lambert-Beer's law (absorbance is proportional to d), and unintentional dilution of the sample in the cuvette affects the determined absorbance in the same way, etc.

It is an important aspect of the present invention that the wavelength shift of a spectrophotometer is determined by forming a Taylor series of a known absorption spectrum or a reference spectrum of a certain component in a sample. After determination of an absorption spectrum of a sample comprising the component with the known absorption spectrum, the wavelength shift is determined.

20

5

10

15

An absorption spectrum of a sample may be defined by a vector $\mathbf{A}_{m}(\lambda)$ comprising at least two elements, each of the elements representing an absorbance of the sample at a specific wavelength λ_{i} .

25

A method in quality control of a spectrophotometer is provided, comprising the steps of

determining with the spectrophotometer a spectrum $A_m(\lambda)$ of a fluid QC sample containing a dye, and

determining a wavelength shift $\Delta\lambda$ from $\mathbf{C}_{\Delta\lambda}(\lambda) \bullet \mathbf{A}_{m}(\lambda)$, in which $\mathbf{C}_{\Delta\lambda}(\lambda)$ is a predetermined coefficient vector previously stored in a memory of the spectrophotometer.

In a preferred embodiment of the method according to the invention the wavelength shift $\Delta\lambda$ is determined after normalisation of the determined spectrum $\mathbf{A}_{m}(\lambda)$ with an estimate of the concentration of the dye.

5

10

20

In a further preferred embodiment of the method according to the invention $\mathbf{C}_{\Delta\lambda}(\lambda)$ has been determined from a combination of a reference spectrum $\mathbf{A}_0(\lambda)$ of a reference sample containing the dye and a first derivative $\mathbf{A}_0'(\lambda)$ of the reference spectrum.

In an approximation, only the first order derivative of the reference spectrum is considered:

15
$$\mathbf{A}_{m}(\lambda) = \mathbf{A}_{0}(\lambda) + \Delta \lambda \mathbf{A}_{0}'(\lambda)$$
 (5)

in which $\mathbf{A}_{0}(\lambda)$ is the reference spectrum, $\mathbf{A}_{0}^{\, \, \, \, }(\lambda)$ is its first derivative with respect to the wavelength λ , $\Delta\lambda$ is the wavelength shift to be determined, and $\mathbf{A}_{m}(\lambda)$ is a spectrum of the sample with the known spectrum $\mathbf{A}_{0}(\lambda)$ measured by the spectrophotometer in which the wavelength shift is to be determined.

 $\Delta\lambda$ may be determined according to various mathematical methods known in the art, e.g. the equation above may be solved for a selected wavelength, the equation may be solved for a set of selected wavelengths and $\Delta\lambda$ be calculated as an average of the solutions for $\Delta\lambda$ to the equation, $\Delta\lambda$ may be determined by a least squares fit, $\Delta\lambda$ may be determined by multivariate analysis, etc.

The invention further provides a method of preparing a spectrophotometer for quality control, comprising the steps of

determining a first reference spectrum $\mathbf{A}_0(\lambda)$ of a reference sample containing a dye of a first concentration with a reference spectrophotometer,

determining a first derivative \mathbf{A}_0 '(λ) of the first reference spectrum of the dye, and

determining from at least the first reference spectrum ${\bf A}_0(\lambda)$ and the first derivative of ${\bf A}_0(\lambda)$ a mathematical parameter from which a wavelength shift $\Delta\lambda$ of the spectrophotometer can be determined, and

storing the mathematical parameter in a memory of the spectrophotometer.

15

20

25

30

10

Further, a spectrophotometer is provided comprising

a memory with a mathematical parameter for the determination of a wavelength shift $\Delta\lambda$ of the spectrophotometer, and

a processor that is connected to the memory and that is adapted to calculate the wavelength shift $\Delta\lambda$ from the mathematical parameter and from a spectrum $\mathbf{A}_m(\lambda)$ determined with the spectrophotometer on a fluid QC sample containing a dye.

The mathematical parameter as mentioned above may comprise the first reference spectrum $\mathbf{A}_0(\lambda)$ and the first derivative $\mathbf{A}_0'(\lambda)$ of the first reference spectrum $\mathbf{A}_0(\lambda)$ at a selected wavelength λ_0 or at a selected set of wavelengths λ_0 , $\lambda_1,\ldots,\lambda_L$, etc., or a parameter derived from the spectra, such as the parameter $\mathbf{C}_{\Delta\lambda}(\lambda)$.

20

35

Preferably, the step of determining a mathematical parameter comprises the steps of

calculating a set of calibration vectors $\boldsymbol{B}_{i}\left(\boldsymbol{\lambda}\right)$ according to

$$\mathbf{B}_{i}(\lambda) = \mathbf{S}_{i}\mathbf{A}_{0}(\lambda) + \mathbf{S}_{i3}\mathbf{A}_{0}^{\dagger}(\lambda) \tag{6}$$

in which i = 1, 2, ..., N (N>1) and s_i and s_{i3} are constants of selected values,

determining a coefficient vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ constituting the mathematical parameter so that each set of corresponding values \mathbf{s}_{i3} , \mathbf{B}_i satisfies:

$$\mathbf{S}_{i3} = \mathbf{c}_{\Lambda\lambda}(\lambda) \bullet \mathbf{B}_{i}(\lambda), \quad i = 1, 2, \dots, N$$
 (7)

The step of determining the wavelength shift $\Delta\lambda$ may comprise the step of calculating $\Delta\lambda$ from $\mathbf{C}_{\Delta\lambda}(\lambda) \bullet \mathbf{A}_m(\lambda)$.

Since the parameter $\Delta\lambda$ is proportional to a total concentration c_{qc} of the dye, $\Delta\lambda$ is typically normalised with c_{qc} or an approximation to c_{qc} , e.g. when the dye is a two-component dye, such as Sulforhodamine B, $\Delta\lambda$ is preferably normalised with a concentration of a first component of the dye s_1 . The normalisation of $\Delta\lambda$ with s_1 is desirable when there is a difference between the concentration of the dye in a reference sample from which the reference spectrum was determined, and the concentration of the dye in the QC sample.

Thus, in a preferred embodiment of the spectrophotometer according to the invention, the mathematical parameter stored in the memory constitutes a vector $\mathbf{C}_{\Delta_{\lambda}}(\lambda)$ from which the wavelength shift $\Delta\lambda$ may be determined.

According to a second important aspect of the invention, the QC sample comprises a dye with two components in a chemical equilibrium where the ratio between the concentration of each component varies with the total concentration of the dye. In this case the shape of the absorption spectrum is dependent on the total concentration of the dye. This characteristic of the dye makes it possible to distinguish between a concentration measurement error caused by undesired dilution of the sample in the cuvette, and a measurement error caused by light path changes in the cuvette.

5

10

Thus, the method of preparing a spectrophotometer for quality control may comprise determining a first refer-15 ence spectrum $A_{01}(\lambda)$ of a reference sample containing the dye in a first concentration and determining a second reference spectrum $\mathbf{A}_{02}(\lambda)$ of a reference sample containing the dye in a second concentration with the reference spectrophotometer, the dye comprising a first 20 component and a second component in chemical equilibrium. Mathematically two model spectra $A_1(\lambda)$ and $A_2(\lambda)$ that represent spectral information about the first and the second component, respectively, may be derived from the first and second reference spectra $\mathbf{A}_{01}(\lambda)$ and $\mathbf{A}_{02}(\lambda)$ 25 in such a way that the spectra of the reference samples can be calculated as a weighted sum of $A_1(\lambda)$ and $A_2(\lambda)$. For example, $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$ may be the individual spectra from the two components, respectively, of the dye, 30 or, $A_1(\lambda)$ may be the sum of the individual spectra from the two components while $A_2(\lambda)$ may be the difference between the individual spectra of the two components, etc. Preferably, $A_1(\lambda)$ and $A_2(\lambda)$ are determined from reference spectra $\mathbf{A}_{01}(\lambda)$ and $\mathbf{A}_{02}(\lambda)$ by Principal Components Analysis (PCA). 35

11

The spectrum $A_m(\lambda)$ determined by the spectrophotometer is then given by

$$\mathbf{S} \quad \mathbf{A}_{\mathbf{m}}(\lambda) = \mathbf{S}_{1}\mathbf{A}_{1}(\lambda) + \mathbf{S}_{2}\mathbf{A}_{2}(\lambda) + \Delta\lambda \mathbf{A}_{0}'(\lambda)$$
 (8)

Each of the parameters s_1 , s_2 , and $\Delta\lambda$ may be determined by mathematical methods, such as multivariate analysis on data obtained from reference samples. The step of determining a mathematical parameter may comprise the steps of

calculating a set of vectors $\mathbf{B_i}(\lambda)$ from

15
$$\mathbf{B}_{i}(\lambda) = \mathbf{S}_{i1} \mathbf{A}_{1}(\lambda) + \mathbf{S}_{i2} \mathbf{A}_{2}(\lambda) + \mathbf{S}_{i3} \mathbf{A}_{0}'(\lambda)$$
 (9)

in which i = 1, 2,..., N (N>1) and s_{i1} , s_{i2} and s_{i3} are constants of selected values,

determining a vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ constituting the mathemati-20 cal parameter so that

$$\mathbf{S}_{i3} = \mathbf{C}_{\Delta\lambda}(\lambda) \bullet \mathbf{B}_{i}(\lambda), \qquad i = 1, 2, \dots, N \tag{10}$$

Further, the mathematical parameter may comprise a vec-25 tor $C_1(\lambda)$ fulfilling that

$$\mathbf{S}_{i1} = \mathbf{C}_{i}(\lambda) \bullet \mathbf{B}_{i}(\lambda), \qquad \qquad i = 1, 2, \dots, N \tag{11}$$

and still further, the mathematical parameter may also comprise a vector $C_2(\lambda)$ fulfilling that

$$\mathbf{S}_{i2} = \mathbf{C}_{2}(\lambda) \bullet \mathbf{B}_{i}(\lambda), \qquad \qquad i = 1, 2, \dots, N \tag{12}$$

30

10

The method in quality control of a spectrophotometer may utilise a QC sample containing the dye in a known concentration $c_{\rm qc}$ and comprising the first and second components, and may further comprise the steps of

5

calculating parameters s_1 and s_2 from

$$\mathbf{S}_{1} = \mathbf{C}_{1}(\lambda) \bullet \mathbf{A}_{m}(\lambda) \tag{13}$$

10
$$s_2 = C_2(\lambda) \cdot A_m(\lambda)$$
 (14)

in which $C_1(\lambda)$ and $C_2(\lambda)$ are the predetermined vectors previously stored in the memory of the spectrophotometer, and

15

calculating an estimated concentration \mathbf{c}_{est} of the dye from

$$C_{est} = a S_1 + b S_2 \tag{15}$$

20

in which a and b are predetermined constants previously stored in the memory of the spectrophotometer, and s_1 and s_2 represents concentrations of a first and a second component, respectively, of the dye.

25

Likewise, in a preferred embodiment of the invention the memory of the spectrophotometer may further comprise vectors $C_1(\lambda)$ and $C_2(\lambda)$ fulfilling the equations (13) and (14).

30

The memory may also comprise predetermined constants a and b and the processor may be further adapted to calculate the concentration $c_{\rm est}$ of the dye according to equation (15)

13

 $C_{est} = a s_1 + b s_2$

WO 99/66310

5

10

15

20

25

It is preferred that the dye has a spectrum with a significant absorbance peak with a steep flank within the measurement range of the spectrophotometer in order to accurately determine small wavelength shifts. For example, when the sample to be analysed is blood, a wavelength shift of 0.05 nm is sufficient to cause an inaccurate determination of several blood parameters, such as ctHb, sO₂, FO₂Hb, FHHb, FCOHb, FMetHb, etc.

PCT/DK99/00313.

Further, it is preferred that the spectrum of the QC sample resembles spectra of samples, which the spectrophotometer in question is intended to analyse so that performance of the instrument can be monitored.

For example, in blood analysis important blood components have significant absorbances in the wavelength range from 480 to 670 nm. Thus, a dye with a spectrum resembling a blood spectrum and having a significant absorbance peak in the range from 400 to 800 nm, preferably from 480 to 670 nm, and having a steep absorbance flank, such as a flank having steepness larger than 40 mAbs/nm, preferably larger than 50 mAbs/nm for a light path length of 100 $\mu\text{m},$ is preferred for use in the methods according to the present invention. The dye should, preferably, also have a molar extinction coefficient in the range from 10,000 to 100,000.

The dye may belong to one of several chemical classes, 30 such as cyanine dyes, azacyanine dyes, triarylmethine dyes, acridine dyes, azine dyes, oxazine dyes, thiazine dyes, xanthene dyes, etc. Dyes belonging to the first four classes are typically cationic dyes being water 35 soluble due to the molecule's positive charge. The xan-

WO 99/66310

20

25

30

35

14

PCT/DK99/00313

thene dyes include the cationic and neutral rhodamines and the anionic sulforhodamines among which Sulforhodamine B is a preferred dye.

According to a preferred embodiment of the invention, the spectrum of reference samples containing the dye in at least two different concentrations is determined, e.g. by an accurate reference instrument of the same type as the spectrophotometer to be quality controlled, at a selected set of wavelengths. Then the coefficient vectors $\mathbf{C_1}(\lambda)$, $\mathbf{C_2}(\lambda)$ and $\mathbf{C_{\Delta\lambda}}(\lambda)$ and the constants a and b are determined, e.g. by multivariate analysis, and stored at the time of manufacture in the memory of the spectrophotometers to be quality controlled by fluid QC samples when put into their normal use.

On manufacture of a QC sample the concentration c_{qc} , the ratio s_2/s_1 denoted Q_{ref} and an initial wavelength shift $\Delta\lambda_{qc}$ may be determined by a reference spectrophotometer. The initial wavelength shift of the QC sample emerges mainly from a variation in the composition of the solvent of the dye in the QC sample.

A label, such as a bar-code label, a magnetic label, etc, may be attached to each of the QC samples containing one or more of the values c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ in question. Alternatively one or more of the values may be printed in a bar code on a paper sheet following a set of QC samples. The values appearing on the labels or paper sheet are designated assigned values.

During quality control of a specific spectrophotometer, the assigned values of $c_{qc},\ Q_{ref}$ and $\Delta\lambda_{qc}$ are read by the spectrophotometer and the values are stored in its memory. Then the spectrum of the QC sample is determined

15

and $s_{\scriptscriptstyle 1},~s_{\scriptscriptstyle 2},~{\rm and}~\Delta\lambda$ are determined as previously described. The determined values for $Q_{\rm est}$ = $s_{\scriptscriptstyle 2}/s_{\scriptscriptstyle 1},~\Delta\lambda$ and $c_{\rm est}$ are also calculated and compared to the assigned values of $Q_{\rm ref},~\Delta\lambda_{\rm qc}$ and $c_{\rm qc},$ respectively.

5

10

15

A possible dilution of the QC sample may be determined from a difference between $Q_{\rm est}$ and $Q_{\rm ref}$, and the combined effect of dilution and deviations in length d of the light path through the cuvette may be determined from a difference between $c_{\rm est}$ and $c_{\rm qc}$.

The estimated parameter values, such as $\Delta\lambda$, c_{est} , and Q_{est} , may be used for determination of parameter values of samples, the analysis of which the spectrophotometer is intended for, so that the outcome of the quality control procedure can be reported by the instrument in quantities meaningful for an operator of the instrument.

- For example, in an oximeter for determination of blood parameter values, the theoretical modifications to one or several predetermined standard blood spectra caused by a measurement error corresponding to one of the parameters $\Delta\lambda$, c_{est} , and Q_{est} determined in the quality control procedure may be calculated by the oximeter. From the modified spectra, the oximeter may calculate corresponding blood parameter values to be reported to the operator of the instrument.
- 30 The predetermined standard blood spectra may either be stored in the memory of the oximeter, or they may be derived mathematically by the processor in the oximeter from predetermined spectra of each blood component comprised in the standard blood samples.

16

In a preferred embodiment of the invention predetermined control limits for the reported blood parameter values are printed on a sheet of paper following a set of QC samples. The operator may compare blood parameter values reported by the oximeter with the predetermined control limits on the paper sheet, and determine whether the reported values are within the control limits.

The predetermined control limits may also be stored in a label of the QC sample which label is read by the oximeter so that the oximeter is adapted to perform the comparison between the reported blood parameter values and the corresponding control limits.

15

5

According to a third important aspect of the invention, a method for repressing absorption spectra of interfering components or substances in a fluid sample, is also provided.

20

25

In the present context an interfering component in a sample is a component other than the preselected components for which the spectrophotometer is adapted to report parameter values, and the presence of said interfering component in the sample may interfere with the absorption spectrum of at least one of said preselected components.

In a determined sample spectrum, the absorbance $\mathbf{A}_{m}(\lambda)$ recorded at each wavelength λ contains contributions from each of the components in the sample including said interfering components. The magnitude of the contribution and thereby the concentration of each component in the sample is determined according to equation (16) or equation (17) below

17

$$C_{y} = \sum_{j=1}^{J} K_{y} (\lambda_{j}) A_{m} (\lambda_{j})$$
(16)

or the equivalent form

$$5 C_{v} = \mathbf{K}_{v}(\lambda) \cdot \mathbf{A}_{m}(\lambda) (17)$$

The vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$ may be determined mathematically by using methods, such as multivariate data analysis, or solving n equations with n unknowns from data obtained from reference samples. By including one or several interfering components or substances in the reference sample, of which the reference spectrum is determined, one or several of the vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$ corresponding to one or several of the interfering components may be determined. The vector or vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$ corresponding to the interfering components are generally designated $\mathbf{K}_{\mathrm{int}}(\lambda)$ and stored in the memory of the spectrophotometer together with the vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$.

The spectrophotometer may further provide one or several predetermined vectors, $\mathbf{A}_{int}(\lambda)$, representing spectral information of the interfering components. Each $\mathbf{A}_{int}(\lambda)$ is obtained at a reference concentration \mathbf{c}_{ref} , whereby the spectrum of any interfering component may be derived at the determined concentration of the component according to Lambert-Beer's law, equation (1).

In an embodiment of the invention, the effect of the interfering components on determined blood parameter values is minimised by following a three stage process, in the following denoted "repression of spectra of interfering components".

First stage is to determine the concentration of interfering components in the sample. Second stage is to determine a modified spectrum of the sample by subtracting the spectrum of the interfering component of the determined concentration from the measured spectrum $\mathbf{A}_{m}(\lambda)$ of the sample. Third stage is to determine concentrations of blood components c_{ν} and parameter values of blood components from the modified spectrum.

- According to the invention, a spectrophotometer with 10 repression of spectra of interfering components in a fluid sample is provided, for determination of a concentration c_{ν} of a component y of a sample and wherein the memory further comprises
- at least one vector $\mathbf{A}_{int}(\lambda)$ representing spectral information of an interfering component in the sample at a concentration cint, and
- at least one vector $\mathbf{K}_{int}(\lambda)$, and wherein 20

5

15

the processor is further adapted to

calculate the concentration cint of the interfering component according to 25

$$C_{int} = K_{int}(\lambda) \bullet A_{m}(\lambda)$$
 (18)

and if c_{int} is greater than a predetermined threshold value, c_{ref} , modify the measured spectrum $\mathbf{A}_{mod}\left(\lambda\right)$ accord-30 ing to

$$\mathbf{A}_{\text{mod}} (\lambda) = \mathbf{A}_{\text{m}} (\lambda) - \frac{\mathbf{C}_{\text{int}}}{\mathbf{C}_{\text{ref}}} \mathbf{A}_{\text{int}} (\lambda)$$
 (19)

 $\mathbf{A}_{mod}\left(\lambda\right)$ being the modified spectrum, and 35

WO 99/66310

19

determine c_y from the modified spectrum $\boldsymbol{A}_{mod}\left(\boldsymbol{\lambda}\right)$ according to

$$S_{v} = K_{v}(\lambda) \bullet A_{mod}(\lambda)$$
 (20)

whereby the effect of interfering components on determined concentrations c_{ν} is minimised.

The measured spectrum is only modified if the determined concentration of the interfering component is above a predetermined threshold value. This is because the modification of the measured spectrum creates some undesired "process noise" in the modified spectrum, due to an uncertainty in the estimate of the spectrum of the interfering component. This addition of "process noise" in the modified spectrum is only justified when the concentration of the interfering component in the sample is larger than the threshold value.

20

An oximeter for blood analysis may provide several predetermined vectors for interfering components or substances of clinical importance and provide corresponding values of the vectors $\mathbf{K}_{\mathrm{int}}(\lambda)$ in the memory. The interfering components may be chosen among components, which have previously caused significant interference in oximetry measurements, such as Fetal Hemoglobin, Bilirubin, Cardio Green, Evans Blue, Methylene Blue, Intralipid, HiCN, SHb, etc. By repressing the spectra of these components an oximeter with better precision in measurement of blood parameter values than currently available instruments is provided.

20

BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described with reference to the drawings, wherein

5

- Fig. 1 is a block diagram of an oximeter according to the invention,
- Fig. 2 is a schematic diagram of a wet section of an oximeter according to the invention,
- 10 Fig. 3 shows main components of a spectrometer, i.e. the optical part of an oximeter according to the invention,
 - Fig. 4 shows compositions of QC samples levels 1-4.
 - Fig. 5 shows absorption spectra of Sulforhodamine B in
- 15 three concentrations,

spectrometer,

- Fig. 6 shows two normalised model spectra determined with Principal Component Analysis from Sulforhodamine B,
- Fig. 7 is a table comprising parameter values of blood 20 samples each related to one of QC sample levels 1-4,
 - Fig. 8 shows absorption spectra of four standard blood samples related to quality control levels 1-4,
 - Fig. 9 is a graph of a variable F_{neon} plotted against the wavelength of light striking two photodiodes in the
- Fig. 10 shows response curves of photodiodes located in wavelength channels 70, 71 and 72.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

30

25

- Fig. 1 is a block diagram comprising a spectrometer 1 in an oximetry module (not shown) connected to a printed circuit board 2 with a data cable 6 comprising electrical conductors. The printed circuit board 2 con-
- 35 trols and collects data from the spectrometer 1. The

data collected are transmitted to a data processing unit 3 comprising a memory (not shown) and a processor (not shown). Values of predetermined coefficient vectors $\mathbf{C_1}(\lambda)$, $\mathbf{C_2}(\lambda)$ and $\mathbf{C_{\Delta\lambda}}(\lambda)$ are stored in the memory. A barcode reader 5 is adapted to read data from bar-code labels mounted on QC samples or on a paper sheet enclosed with a set of samples, and transmits data to the data processing unit 3 via a data management computer 7. A power supply module 4 supplies power to the oximetry module from a mains connection.

Fig. 2 is a schematic diagram of a wet section of an oximeter according to the invention, wherein a blood sample (not shown) is entered into the oximeter through an inlet probe 20. The sample is transferred to a cuvette 74. A preheater 15 is positioned along the sample path 30 to heat the sample to a substantially constant temperature of 37 °C. Pumps 10 are used to pump liquids and gasses through the wet section.

Fig. 3 shows the main components of the spectrometer 1, wherein a light beam 75 with constant intensity is transmitted from a halogen lamp 70 to the cuvette 74 which comprises the blood or QC sample and is included in a hemolyzer 79. The blood sample is hemolyzed by means of ultrasonic waves. Hemolyzing is a process, which ruptures the walls of the red blood cells in the sample, thereby making the blood cells release their content of hemoglobin. The light beam 75 is transmitted to the cuvette 74 through an infrared filter 71, and a biconvex lens 72. After passing through the cuvette 74, the light beam 75 is transmitted to a measurement section 76, by means of an optical fibre 77. The light beam 75 passes through a thin slit 78, whereby the beam

WO 99/66310

75 is directed towards a concave grating unit 80, diffracting the light beam 75 according to wavelength.

22

PCT/DK99/00313

The concave grating unit 80 focuses light on a photodiode array 83, to which a diffracted light beam 82 is 5 transmitted. The photodiode array 83 may consist of 128 photodiodes, and the array 83 is arranged in such a manner that light comprising a range of wavelengths of approximately 1.5 nm in the diffracted light beam 82, strikes a photodiode (not shown), which converts the 10 light into a current substantially proportional to the light intensity which strikes it. By measuring the value of the current in each of the 128 photodiodes of the photodiode array 83, a discrete intensity spectrum of the light beam 82 after transmission through the 15 sample is produced. From this intensity spectrum an absorption spectrum of the blood sample comprised in the cuvette 74 may be determined by the oximeter.

The absorption spectrum is measured in 128 channels located in the wavelength range 478-672 nm in the preferred embodiment of the invention. A channel is, in the present context, the part of the spectrum which is transmitted to a particular photodiode in the diode array 83.

According to the invention a wavelength shift of the oximeter is determined in the quality control procedure. It is preferred that four different types of quality control samples (QC samples levels 1-4) are provided, cf. Fig. 4. The QC levels comprise Sulforhodamine B in different concentrations. Increased reliability in the quality control of the oximeter is provided by measuring the absorption spectrum of QC samples at several QC levels. By utilising QC samples compared to the oximeter of the oximeter o

30

35

23

prising Sulforhodamine B in different concentrations, it is ensured that the oximeter measures blood parameters correctly over a wide range of component concentrations in blood samples.

5

10

In solution Sulforhodamine B shows long term stability. The steep absorbance flank allows an accurate determination of the wavelength shift of the oximeter, since even very small wavelength shifts produce a large change in the measured absorbance at a given wavelength of a Sulforhodamine B containing sample.

In aqueous solution Sulforhodamine B is a dye with two components in a chemical equilibrium where the ratio between the concentration of each component in the dye varies with the total concentration of the dye. In this case the shape of the absorption spectrum is dependent on the total concentration c_i of the dye. This may be seen in Fig. 5, which shows three absorption spectra $\mathbf{A}_{01}(\lambda)$ 110, $\mathbf{A}_{02}(\lambda)$ 111 and $\mathbf{A}_{03}(\lambda)$ 112 of Sulforhodamine B samples determined at the total concentrations 2.5058 mmol/kg, 1.6705 mmol/kg and 1.0023 mmol/kg, respectively. The Sulforhodamine B samples correspond to QC levels 1-3 as shown in Fig. 4.

25

30

Mathematically, two model spectra $\mathbf{A}_1(\lambda)$ 105 and $\mathbf{A}_2(\lambda)$ 106 as shown in Fig. 6 may be derived from at least two reference spectra, e.g. $\mathbf{A}_{01}(\lambda)$ 110 and $\mathbf{A}_{02}(\lambda)$ 111 of Fig. 5, wherein the two model spectra represent spectral information about a first and a second component, respectively of Sulforhodamine B, in such a way that the spectrum of the dye can be calculated as a weighted sum of $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$.

WO 99/66310

The two model spectra are, preferably, determined by Principal Component Analysis (PCA), whereby two orthogonal vectors are determined constituting the mathematical model spectra, $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$. A set of scores or parameters \mathbf{s}_{i1} and \mathbf{s}_{i2} is also provided by the PCA analysis for each concentration of the dye, as the spectrum of the dye at a concentration \mathbf{c}_i can be calculated as a weighted sum of model spectra $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$ and their corresponding scores or weights \mathbf{s}_{i1} and \mathbf{s}_{i2} .

10

15

20

5

The PCA analysis may be provided by several computer programs, which are commercially available. The program used in the present embodiment is the "Unscrambler". The two model spectra $\mathbf{A}_1(\lambda)$ 105 and $\mathbf{A}_2(\lambda)$ 106 shown in Fig. 6 are determined by PCA from the three reference spectra $\mathbf{A}_{01}(\lambda)$, $\mathbf{A}_{02}(\lambda)$ and $\mathbf{A}_{03}(\lambda)$ with "Unscrambler".

The reference concentrations of the dye in the solution at which the reference absorption spectra $A_{01}(\lambda)$, $A_{02}(\lambda)$ and $A_{03}(\lambda)$ are measured, are determined from the weight of the dye, Sulforhodamine B in powder form and the volume of the solvent. The reference absorption spectra are determined by measuring the absorption spectra of 5 samples containing Sulforhodamine B at each reference concentration, and determining an average value for the reference spectrum for each concentration. The reference absorption spectra of the samples are measured by a reference oximeter, which by definition has a zero wavelength shift.

30

35

25

In practice, an oximeter not specifically appointed and handled as a reference oximeter will always exhibit some wavelength shift $\Delta\lambda$ whereby a measured absorption spectrum $\mathbf{A}_{\mathbf{m}}(\lambda)$ of a sample will differ slightly from the reference spectrum $\mathbf{A}_{\mathbf{0}}(\lambda)$ of the same sample measured on

the reference oximeter. The relationship between the measured spectrum $\mathbf{A}_{m}(\lambda)$ and a reference spectrum $\mathbf{A}_{0}(\lambda)$ and the model spectra is for small wavelength shifts according to equation (8)

5

$$\mathbf{A}_{m}(\lambda) = \mathbf{S}_{1}\mathbf{A}_{1}(\lambda) + \mathbf{S}_{2}\mathbf{A}_{2}(\lambda) + \Delta\lambda \mathbf{A}_{0}'(\lambda)$$

wherein $\Delta\lambda$ \mathbf{A}_0 (λ) is the first term in a Taylor series of the reference spectrum \mathbf{A}_0 (λ).

10

The first derivative of the reference spectrum \mathbf{A}_0 '(λ) is preferably calculated in approximation as a first derivative of the model spectrum \mathbf{A}_1 '(λ). The approximation is justified since the values of the scores \mathbf{s}_{i1} for the model spectra $\mathbf{A}_1(\lambda)$ are found to be much higher than the values of the scores \mathbf{s}_{i2} for the model spectra $\mathbf{A}_2(\lambda)$, of Sulforhodamine B in relevant concentrations \mathbf{c}_i , so that

$$\mathbf{A}_{0}'(\lambda) = \mathbf{S}_{1}\mathbf{A}_{1}'(\lambda) + \mathbf{S}_{2}\mathbf{A}_{2}'(\lambda) \approx \mathbf{S}_{1}\mathbf{A}_{1}'(\lambda) \tag{21}$$

20

15

whereby the measured spectrum $\boldsymbol{A}_{mi}\left(\boldsymbol{\lambda}\right)$ may be approximated by

$$\mathbf{A}_{mi}(\lambda) = \mathbf{s}_{i1}\mathbf{A}_{1}(\lambda) + \mathbf{s}_{i2}\mathbf{A}_{2}(\lambda) + \Delta\lambda_{i}\mathbf{s}_{i1} \mathbf{A}_{1}'(\lambda)$$
 (22)

25

 $\Delta\lambda_i s_{i1},\ s_{i1},\ s_{i2}$ are the scores or the constants corresponding to a concentration c_i .

Coefficient vectors $\mathbf{C}_1(\lambda)$, $\mathbf{C}_2(\lambda)$ and $\mathbf{C}_{\Delta\lambda}(\lambda)$ are, prefera-30 bly, determined by multivariate analysis from the scores and the corresponding determined absorption spectra.

The multivariate analysis starts by generating a table with 64 rows and 4 columns. The first three columns in this table comprise selected values of either one of the

scores $\Delta\lambda_i s_{i1}$, s_{i1} , s_{i2} , and the last column comprises the corresponding calculated value of the spectrum $\mathbf{A}_{mi}(\lambda)$. Each row constitutes a calibration vector, and the entire table constitutes 64 calibration vectors.

5

WO 99/66310

The 64 values of each score appearing in one and the same column are evenly distributed between:

0 and
$$\frac{1}{\sqrt{A^2(\lambda_j)}}$$

wherein $A^2(\lambda_j)$ denotes the summation of squared absorbances across 128 wavelengths of the particular spectrum that corresponds to a particular score; i.e. the values of the score s_{i1} are evenly distributed between 0 and reciprocal of (square root($A_1^2(\lambda)$).

15

20

The next step in the multivariate analysis comprises to determine from the table the coefficient vector $\mathbf{C}_1(\lambda)$ by Principal Component Regression so that each set of scores \mathbf{s}_{i1} , and the corresponding spectrum $\mathbf{A}_{mi}(\lambda)$, satisfies

$$\mathbf{S}_{i1} = \mathbf{C}_{1}(\lambda) \bullet \mathbf{A}_{mi}(\lambda) \tag{23}$$

From the table the coefficient vector $\mathbf{C_2}(\lambda)$ is deter-25 mined by Principal Component Regression so that each set of scores $\mathbf{s_{i2}}$ and the corresponding spectrum $\mathbf{A_{mi}}(\lambda)$, satisfies

$$\mathbf{S}_{i2} = \mathbf{C}_{2}(\lambda) \bullet \mathbf{A}_{mi}(\lambda) \tag{24}$$

30

From the table the coefficient vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ is determined by Principal Component Regression (PCR) so that each set of scores $\Delta\lambda_i\mathbf{s}_{i1}$ and the corresponding spectra $\mathbf{A}_{mi}(\lambda)$, satisfies

WO 99/66310 PCT/DK99/00313.

$$\Delta \lambda_i \ \mathbf{s}_{i1} = \mathbf{C}_{\Delta \lambda}(\lambda) \bullet \mathbf{A}_{mi}(\lambda)$$
 (25)

Further, it is assumed that the following relation between the calculated scores and a total concentration, c_i of the dye exists

$$c_i = a s_{i1} + b s_{i2}$$
 (26)

wherein constants a and b may be found by several methods, preferably, by inserting the determined scores from the total concentrations, c_i of the dye of concentrations 2.5058 mmol/kg and 1.0023 mmol/kg in equation (26) and solve the resulting two equations with two unknown quantities, for a and b. The determined values of a, b are: a=0.1425; b=0.0931, so that equation (26) is determined as

$$c_i = 0.1425 \ s_{i1} + 0.0931 \ s_{i2}$$
 (27)

20

25

The validity of equation (27) may be checked by inserting scores s_{i1} , s_{i2} from reference solutions with total concentrations c_i of Sulforhodamine B not used in the determination of a and b. Thereby, the validity of equation (27) has been confirmed experimentally.

In field use of the spectrophotometer the coefficient vectors are applied as follows:

From the coefficient vector, $\mathbf{C}_1(\lambda)$ a score or parameter value, \mathbf{s}_1 may be determined according to equation (13)

$$s_1 = C_1(\lambda) \bullet A_m(\lambda)$$

28

wherein $\mathbf{A}_{m}(\lambda)$ is a measured spectrum of a QC/reference sample.

From the coefficient vector, $\mathbf{C}_2(\lambda)$ a score or parameter value, \mathbf{s}_2 may be determined according to equation (14)

$$s_2 = C_2(\lambda) \bullet A_m(\lambda)$$

wherein $\mathbf{A}_{m}(\lambda)$ is a measured spectrum of a QC/reference sample.

From the coefficient vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ a score or parameter value $\Delta\lambda s_1$, which is proportional to the wavelength shift may be determined according to

15

30

$$\Delta \lambda \, \mathbf{s}_{1} = \mathbf{C}_{\Delta \lambda}(\lambda) \, \bullet \, \mathbf{A}_{m}(\lambda) \tag{28}$$

wherein $A_m(\lambda)$ is a QC/reference sample.

Determined s_1 , s_2 scores may be interpreted as the equivalent concentrations of the first and the second component of the dye, respectively. The first component corresponds to the mathematical model spectrum $\mathbf{A}_1(\lambda)$, and the second component corresponds to the mathematical cal model spectrum $\mathbf{A}_2(\lambda)$.

The determined coefficient vectors $\mathbf{C}_{\Delta\lambda}(\lambda)$, $\mathbf{C}_1(\lambda)$ and $\mathbf{C}_2(\lambda)$ are stored in a matrix in the memory of the oximeter at the time of manufacture. The determined constants a, b are also stored in the memory of the oximeter at the time of manufacture.

QC samples are, preferably, manufactured in lots, which may comprise 40,000-50,000 samples. The lot values of c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ are, preferably, determined during

29

manufacturing by measuring 5-10 samples on 3 reference oximeters. The oximeters have been adjusted to report exact parameter values on a standard blood sample.

Average values of each of the measured parameters c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ are calculated and preferably stored on a bar-code label attached to each of the QC samples.

During a quality control procedure of an oximeter in normal operation, e.g. at a hospital, the values of c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ are read from the bar-code label of the QC sample by a bar-code reader and stored in the memory of the oximeter.

Then the absorption spectrum of the QC sample is determined. An estimated concentration of Sulforhodamine B in the QC sample may be determined by the measured absorption spectrum $\mathbf{A}_{\!\!\mathbf{m}}(\lambda)$ by equation (26) as

 $c_{est} = 0.1425 s_1 + 0.0931 s_2$

since the values of s_1 and s_2 can be determined by the measured absorption spectrum $\mathbf{A}_{m}(\lambda)$ and the vectors $\mathbf{C}_{1}(\lambda)$ and $\mathbf{C}_{2}(\lambda)$ according to equations (13) and (14). The ratio between s_1 and s_2 is determined and denoted Q_{est} .

An estimate of a score proportional to the wavelength shift of the oximeter is provided by equation (25)

30 $\Delta \lambda s_1 = C_{\Delta \lambda}(\lambda) \cdot A_m(\lambda)$.

Since the value of s_1 has been determined, the value of the wavelength shift of the oximeter is determined by dividing the score $\Delta\lambda$ s_1 with s_1

25

5

$$\Delta \lambda = \frac{C_{\Delta \lambda} (\lambda) \cdot A_{m}(\lambda)}{S_{s}}$$
 (29)

The length of the cuvette light path d_0 in the oximeter is, preferably, determined by measuring an absorption spectrum $\mathbf{A}_m(\lambda)$ of a Sulforhodamine B reference solution. The concentration of Sulforhodamine B, c_{ref} , is, preferably, provided as an assigned value.

To determine the value of d_0 , the absorption spectrum $\mathbf{A}_{\mathbf{m}}(\lambda)$ of the reference solution is measured, and an estimate of the concentration $\mathbf{c}_{\mathrm{est}}$ of the dye is calculated by the processor in the oximeter according to equations (26), (13), (14) by utilising predetermined coefficient vectors $\mathbf{C}_{\Delta\lambda}(\lambda)$, $\mathbf{C}_1(\lambda)$ and $\mathbf{C}_2(\lambda)$ and constants a, b stored in the memory of the oximeter as previously described.

The concentration c_{est} of the reference solution determined by the oximeter is utilised to calculate an actual value of the cuvette light path length, d_0 , in the oximeter according to

$$d_0 = d_{ref} \frac{C_{est}}{C_{ref}} \tag{30}$$

wherein d_{ref} is a reference value of the cuvette light path length, which is previously stored in the memory of the oximeter. The calculated value of d_0 is subsequently stored in the memory of the oximeter.

30 The difference between the value of $\Delta\lambda$ determined for the Sulforhodamine B reference solution and the assigned value $\Delta\lambda_{ref}$ for the reference solution is util-

ised to shift the subsequently measured spectra along the wavelength axis.

The absorbance $A(\lambda)$ of a fluid sample is measured by the oximeter by determining the logarithm of a light intensity I_0 transmitted through a transparent aqueous reference solution divided by the light intensity I transmitted through the fluid sample in question, according to equation (2)

10

20

35

$$A(\lambda) = \log \frac{I_0}{T}.$$

 I_{o} is denoted the zero point intensity, and is measured automatically at every calibration of the oximeter with said reference solution.

During a quality control of the oximeter, a determined value of $c_{\rm est}$ may be compared with the corresponding value $c_{\rm qc}$ read from the label of the QC sample. A difference between the values may originate from two of the variables in Lambert-Beer's law, equation (1)

$$A(\lambda) = \varepsilon(\lambda) c d.$$

25 It applies that either the cuvette light path length d in the oximeter is different from the d_0 value stored in the memory of the oximeter, which causes a higher or a lower value of the measured absorbance, or the measured concentration $c_{\rm est}$ of the dye deviates from the value of $c_{\rm gc}$.

The determined concentration c_{est} may deviate from the value of c_{qc} due to errors in the wet section of the oximeter, such as defect tubes, defect pumps, errors in the cuvette, etc. It may all lead to undesired dilution

WO 99/66310 PCT/DK99/00313.

32

of the sample. However $c_{\rm est}$ may also be different from $c_{\rm qc}$ due to an incorrect light path length $d_{\rm 0}$ of the cuvette.

If there is a difference between $c_{\rm est}$ and $c_{\rm qc}$, and the value of $Q_{\rm ref}$ being equal to $Q_{\rm est}$, the difference between the estimated concentration and the reference concentration values may be caused by a difference between the light path length d_0 of the cuvette as calculated during calibration and the reference value $d_{\rm ref}$ of the length determined during manufacture.

If there is a difference between $c_{\rm est}$ and $c_{\rm qc}$, the value of $Q_{\rm ref}$ being different from $Q_{\rm est}$, the sample may be diluted. A dilution causes the concentration of the dye to be smaller than $c_{\rm ref}$ and further causes a shift in the chemical equilibrium between the components s_1 and s_2 which causes the value of $Q_{\rm est}$ to deviate from $Q_{\rm ref}$.

15

The determined differences between measured parameters 20 $\Delta\lambda,~c_{\text{est}},~\text{and}~Q_{\text{est}}$ and the corresponding parameters read from the bar-code label of the QC sample may be reported by the oximeter to the operator e.g. by means of a printer. A printed message may comprise information as to which of the measured parameters caused the QC 25 sample to fail the quality control. Together with a printout of the failing parameter a message suggesting which part of the oximeter needs repair or service, may be included. For example, the printed message may recommend a repair of the measurement section 76 of the 30 spectrometer 1, if the measured wavelength shift $\Delta\lambda$ is larger than a predetermined threshold value stored in the memory of the oximeter.

33

In a preferred embodiment of the invention the measured parameters of the QC sample are used to modify spectra of standard blood samples corresponding to either of the QC levels 1-4.

5

10

15

35

In Fig. 7 the figures in columns 2-7 of each row define a standard blood sample composition, and column 1 shows the related QC level. For each of the four standard blood samples a corresponding standard blood spectrum as shown in Fig. 8 may be derived mathematically by the processor in the oximeter from predetermined spectra of each blood component comprised in the standard blood samples. The predetermined spectra of each blood component are, preferably, stored in the memory of the oximeter during manufacture.

Each blood component parameter value in the table in Fig. 7 has an attached plus/minus limit value. The limit values are calculated errors, which would be produced by a measurement of parameter values in the stan-. 20 dard blood sample with an oximeter having a wavelength shift of plus and minus 0.05 nm, respectively, as the only measurement error. For example, the value of blood component FCOHb in a level 1 sample would be measured 25 to 5.34 % or 6.66 % instead of the correct value of 6.00 %. Thus, even very small wavelength shifts in the oximeter, introduces significant errors in the measured blood parameter values, thereby illustrating the importance of quality controlling the oximeter for wavelength shifts. 30

By determining the modifications to the mathematically derived standard blood spectrum related to the level of the actual QC sample under test resulting from the parameters $\Delta\lambda$, c_{est} and optionally also Q_{est} , determined in

WO 99/66310

5

10

15

the QC procedure, the oximeter may use the modified spectrum to calculate corresponding blood parameter values. The parameter values are reported to the operator of the oximeter, and the operator may compare them with assigned control limits for the actual QC level. The effect of the instument errors revealed in the QC procedure on values reported for a blood sample with unknown blood parameter values may, e.g., appear from the deviations between the reported parameter values and the values of the relevant standard blood sample of Fig. 7.

Fig. 8 shows absorption spectra for each of standard blood sample, which absorption spectra are used in the oximeter for quality control levels 1-4. The spectra corresponding to levels 1-4 are 120, 121, 122, 123, respectively. Each spectrum has a corresponding $c_{\rm ref}$ value corresponding to a Sulforhodamine B concentration.

- The above modification to the standard blood spectra shown in Fig. 8 resulting from the parameter $\Delta\lambda$ is a shift along the wavelength axis corresponding to the difference between $\Delta\lambda$ and $\Delta\lambda_{qc}$, $\Delta\lambda_{qc}$ being either an assigned value or a predetermined fixed value stored in the memory of the oximeter. The modification of the standard blood spectra resulting from the parameter c_{est} is a modification of the individual absorbances with the ratio c_{est}/c_{ref} .
- 30 By adopting this method of converting determined measurement errors introduced by the oximeter into parameter values of blood samples, instrument errors are reported in terms which are easily understood by the operator of the oximeter.

By noting which of the blood parameters failed the control, it may be possible to determine which of the measured parameters $\Delta\lambda$, c_{est} and Q_{est} caused the quality control to fail, and thereby determine which part of the oximeter that needs repair or service.

The relation between blood parameters that failed the quality control by being outside their corresponding control limits and the measured values of parameters $\Delta\lambda$, c_{est} , and Q_{est} and thereby an error diagnosis of the oximeter may, preferably, be comprised in a service manual for a repair technician.

According to the invention a method is provided for repressing absorption spectra of one or several interfering components or substances contained in a blood sample in the oximeter. Preferably, the oximeter is
adapted to repress the spectrum of Fetal Hemoglobin,
which is known to cause significant interference in oximetry measurements.

In a determined blood sample spectrum, the absorbance $\mathbf{A}_{m}(\lambda)$ recorded at each wavelength λ contains contributions from each component in the sample. Interfering components are naturally treated as the other components. The magnitude of the contribution and thereby the concentration of each component in the sample is determined according to equation (17)

30
$$C_v = K_v(\lambda) \cdot A_m(\lambda)$$
.

5

25

The vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$ are predetermined and stored in the memory of the spectrophotometer.

WO 99/66310

By including a Fetal Hemoglobin component in a blood sample, of which the reference spectrum is to be determined, a vector $\mathbf{K}_{\text{fetal}}(\lambda)$ corresponding to the concentration of Fetal Hemoglobin in the sample, is determined.

5

10

Preferably, the oximeter further provides a predetermined vector $\mathbf{A}_{\text{fetal}}(\lambda)$, representing the difference spectrum between Adult Hemoglobin and Fetal Hemoglobin. The vector $\mathbf{A}_{\text{fetal}}(\lambda)$ is, preferably, determined at a reference concentration $\mathbf{c}_{\text{fetal}}$ of 1 mmol/L.

The effect on determined blood parameter values due to the presence of Fetal Hemoglobin in the blood sample, is minimised by repressing the spectrum of Fetal Hemoglobin.

The first stage in the repression process comprises the determination of the concentration of Fetal Hemoglobin in the blood sample, according to equation (18)

20

15

$$C_{\text{fetal}} = K_{\text{fetal}}(\lambda) \cdot A_{m}(\lambda)$$
.

The second stage comprises the determination of a modified spectrum by subtracting the difference spectrum at the determined concentration from the measured spectrum ${\bf A}_{\rm m}(\lambda)$ of the blood sample, if ${\bf c}_{\rm fetal}$ is greater than a predetermined threshold value, according to equation (19)

30
$$\mathbf{A}_{mod}(\lambda) = \mathbf{A}_{m}(\lambda) - \frac{C_{fetal}}{1} \mathbf{A}_{fetal}(\lambda)$$

wherein $\mathbf{A}_{mod}(\lambda)$ is the modified spectrum and $\mathbf{c}_{ref}=1$ mmol/L.

If c_{fetal} is smaller than the predetermined threshold value the modified spectrum is set equal to the measured spectrum $A_m(\lambda)$.

The third stage comprises the determination of concentrations of blood components c_y from the modified spectrum $\mathbf{A}_{mod}(\lambda)$, whereby the effect of Fetal Hemoglobin in the blood sample on determined concentrations c_y of blood components is minimised.

10

By repressing the spectrum of Fetal Hemoglobin automatically, an oximeter is provided with an increased precision in measured blood parameter values, and an easier operation than currently available instruments.

15

35

Fig. 9 is a graph of a variable F_{neon} plotted against the wavelength of light striking two photodiodes in wavelength channels 70 and 71 of the photodiode array 83 in the spectrometer 1 shown in Fig. 3. The spectrometer 1 comprises a neon glow lamp (not shown), which emits at least one spectral line at a highly accurate reference wavelength of 585.25 nm, suitably positioned within the preferred wavelength range from 480 to 670 nm. The accurate wavelength of the emitted spectral line is used in the oximeter as a reference wavelength against which the location of the 128 wavelength channels of the array 83 is adjusted. To utilise the reference wavelength a variable F_{neon} is defined as

30
$$F_{neon} = R(70)/R(71)$$

(31)

wherein R(70) and R(71) are the magnitudes of the current or the response in each of the photodiodes located in channels 70 and 71. $F_{\rm neon}$ is also equal to the ratio between the light intensity striking photodiodes in

channels 70 and 71, due to the linear relationship between the current in a photodiode and the light intensity which strikes it. For example, if $F_{\rm neon}=1$ the light intensity striking diode 70 is equal to the light intensity striking diode 71, which means that the reference wavelength is positioned exactly between the channels 70 and 71. $F_{\rm neon}$ is used as a variable that defines the position of the light of the reference wavelength emitted from the neon lamp relative to the wavelength channels in the spectrometer 1. This characteristic of $F_{\rm neon}$ is utilised during field operation of the oximeter, where the value of $F_{\rm neon}$ is measured at predetermined time intervals, and compared with a reference value $F_{\rm cal}$ stored in the memory of the oximeter during manufacture.

5

10

15

The spectrometer 1 is scanned with light emitted from a high precision monochromator in the wavelength range 585.25 +/- 7.5 nm during manufacture. A response curve for the photodiode located in channel 71 is measured. 20 An example of a measured response curve is 131 shown in Fig. 10. A calibration algorithm comprised in the memory of the oximeter calculates a corresponding response curve for channel 70 by shifting the wavelength axis. The calibration algorithm further calculates a wave-25 length calibration table comprising values of the variable F_{neon} and the corresponding value of the wavelength of light emitted from the monochromator by using the determined response curves of channels 70 and 71. The oximeter stores determined values of the wavelength 30 calibration table in the memory. A reference value of F_{neon} , denoted F_{cal} , is determined during manufacture by activating the neon lamp and measuring the response of channels 70 and 71, as previously described. The referWO 99/66310 PCT/DK99/00313

ence value of F_{cal} is stored in the memory of the oximeter.

The data comprised in the wavelength calibration table may be displayed graphically as shown in Fig. 9.

A calibration program measures the current temperature of the spectrometer 1 between two blood sample measurements in normal operation of the oximeter. The cuvette is always cleaned with a transparent rinse solution between two blood sample measurements. The current measured temperature of the spectrometer 1 is compared with a previous temperature measurement which was performed at the time of the previous neon lamp activation and stored in the memory of the oximeter. The calibration program determines whether the current temperature value deviates more than 0.3 °C from the previous temperature value, and performs a measurement of the current value of $F_{\rm neon}$ if this is the case.

The graph in Fig. 9 is now used to illustrate how a wavelength shift of the oximeter is determined and compensated during a period of time between two blood sample measurements, wherein the cuvette is rinsed. A first value of F_{neon} denoted F_{cal} corresponding to a first value of the wavelength denoted λ_{cal} are shown in the graph, and the value of F_{cal} is determined, as previously described. A second value of the variable F_{neon} denoted F_{act} may be measured by the oximeter between two blood sample measurements. By utilising the predetermined wavelength calibration table comprised in the memory of the oximeter a second value of wavelength λ denoted λ_{act} corresponding to F_{act} may be determined. The value of λ_{act} may be determined from the discrete values of the variable λ comprised in the calibration table

according to well-known mathematical interpolation methods such as linear interpolation, polynomial interpolation, cubic spline interpolation, etc.

- A wavelength shift $\Delta\lambda$ of the spectrometer may be determined from the difference between the determined value λ_{act} and the calibration value λ_{cal} . The determined wavelength shift $\Delta\lambda$ of the spectrometer 1 may be utilised to compensate a measured absorption spectrum $\mathbf{A}_{m}(\lambda)$ of a fluid sample by determining a modified absorption spectrum $\mathbf{A}_{modi}(\lambda)$ of the sample, wherein the effect of the determined wavelength shift $\Delta\lambda$ on absorbances in the measured spectrum $\mathbf{A}_{m}(\lambda)$ is removed.
- 15 The modified spectrum is, preferably, determined by first utilising a cubic spline function to generate interpolated absorbance values between the discrete values at the 128 wavelengths in the measured spectrum $\mathbf{A}_{\mathbf{m}}(\lambda)$. The modified spectrum $\mathbf{A}_{\mathrm{modi}}(\lambda)$ is determined by shifting the wavelength of each measured absorbance value in $\mathbf{A}_{\mathbf{m}}(\lambda)$ sequentially with an amount equal to $\Delta\lambda$ and determine a corresponding interpolated absorbance value for the modified spectrum.
- The provision of a spectral lamp, preferably a neon lamp, having at least one spectral line within a desired wavelength range enables the oximeter to perform highly accurate measurements of the wavelengths of light absorbed by a sample by comparing the determined wavelength of said at least one spectral line with the assigned wavelength of the spectral line stored in the memory of the oximeter, calculating the possible wavelength shift, and compensating the determined absorbance of the sample for said wavelength shift. Accordingly, the determined absorption spectrum by the spec-

WO 99/66310 PCT/DK99/00313

41

trometer 1 is being compensated for wavelength shifts resulting from manufacturing tolerances and temperature drift during the use of the oximeter, thereby providing accurate measurements of blood parameter values.

5

Fig. 10 shows three response curves 130, 131 and 132 of photodiodes located in the corresponding wavelength channels 70, 71 and 72. The x-axis of the graph is the wavelength in nm of the light striking the diodes, and the y-axis of the graph is counts. The wavelength distance between the peak points of e.g. response curve 130, 131 is approximately 1.5 nm, which is the channel distance between all the 128 adjacent wavelength channels of the diode array 13.

15

10

PCT/DK99/00313

CLAIMS

WO 99/66310

 A method in quality control of a spectrophotometer, comprising the steps of

5

determining with the spectrophotometer a spectrum $\boldsymbol{A}_{\!\!\!\!m}\left(\boldsymbol{\lambda}\right)$ of a fluid QC sample containing a dye, and

10

determining a wavelength shift $\Delta\lambda$ from $C_{\Delta\lambda}(\lambda)$ • $A_m(\lambda)$, in which $C_{\Delta\lambda}(\lambda)$ is a predetermined coefficient vector previously stored in a memory of the spectrophotometer.

- 2. A method according to claim 1, wherein the wavelength shift $\Delta\lambda$ is determined after normalisation of the determined spectrum $\mathbf{A}_{m}(\lambda)$ with an estimate of the concentration of the dye.
- 3. A method according to claim 1 or 2, wherein $\mathbf{C}_{\Delta\lambda}(\lambda)$ has been determined from a combination of a reference spectrum $\mathbf{A}_0(\lambda)$ of a reference sample containing the dye and a first derivative \mathbf{A}_0 '(λ) of the reference spectrum.
- 25 4. A method according to any of the preceeding claims, wherein the QC sample has an assigned wavelength shift $\Delta\lambda_{\rm qc}$, which method further comprises the step of comparing $\Delta\lambda$ with $\Delta\lambda_{\rm qc}$.
- 30 5. A method according to any of the preceeding claims, wherein the QC sample has a spectrum with a significant absorbance peak with a steep flank.
- 6. A method according to any of the preceding claims, wherein the QC sample has a known dye concentra-

43

tion c_{qc} and the dye comprises a first and a second component, the method further comprising the steps of

5 calculating parameters s_1 and s_2 from

$$s_1 = C_1(\lambda) \bullet A_m(\lambda)$$

$$s_2 = C_2(\lambda) \cdot A_m(\lambda)$$

10

in which $C_1(\lambda)$ and $C_2(\lambda)$ are predetermined vectors previously stored in the memory of the spectrophotometer, and

calculating an estimated concentration c_{est} of the dye from

$$C_{est} = a s_1 + b s_2$$

- in which a and b are predetermined constants previously stored in the memory of the spectrophotometer.
- 7. A method according to claim 6, further comprising the step of comparing $c_{\rm est}$ with $c_{\rm qc}$.
 - 8. A method according to claims 6 or 7, further comprising the step of calculating a variable $Q_{\rm est} = s_2/s_1$.

30

9. A method according to any of claims 6-8, wherein the QC sample has an assigned value of $s_2/s_1=Q_{qc}$, which method further comprises the step of comparing Q_{est} with Q_{qc} .

30

- 10. A method according to any of the preceding claims, wherein the spectrophotometer is an oximeter.
- 11. A method according to claim 10, wherein spectra are measured in the wavelength range from 400 to 800 nm.
- 12. A method according to claim 10 or 11, further comprising the step of determining estimated errors in blood parameter values reported by the oximeter caused by the wavelength shift $\Delta\lambda$, optionally corrected by the assigned wavelength shift $\Delta\lambda_{\rm qc}$.
- 13. A method according to any of claims 10-12, further comprising the step of determining estimated errors in blood parameter values reported by the oximeter caused by a difference between $c_{\rm est}$ and $c_{\rm qc}$.
- 14. A method according to any of claims 10-13, further comprising the step of determining estimated errors in blood parameter values reported by the oximeter caused by a difference between $Q_{\rm est}$ and $Q_{\rm qc}$.
- 15. A method of preparing a spectrophotometer for quality control, comprising the steps of

determining a first reference spectrum $A_{01}(\lambda)$ of a reference sample containing a dye in a first concentration with a reference spectrophotometer,

- determining a first derivative \mathbf{A}_{01} (λ) of the first reference spectrum, and
- determining from at least the first reference spectrum $\mathbf{A}_{01}(\lambda)$ and the first derivative $\mathbf{A}_{01}(\lambda)$ a

mathematical parameter from which a wavelength shift $\Delta\lambda$ of the spectrophotometer can be determined, and

- storing the mathematical parameter in a memory of 5 the spectrophotometer.
- A method according to claim 15, wherein the step 16. of determining a mathematical parameter comprises the steps of 10

calculating a set of calibration vectors $\mathbf{B}_{i}(\lambda)$ according to

15
$$\mathbf{B}_{i}(\lambda) = \mathbf{s}_{i}\mathbf{A}_{01}(\lambda) + \mathbf{s}_{i3}\mathbf{A}_{01}'(\lambda)$$

in which i = 1, 2, ..., N (N>1) and s_i and s_{i3} are constants of selected values,

determining a coefficient vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ constitut-20 ing the mathematical parameter so that each set of corresponding values si3, Bi satisfies:

$$s_{i,3} = C_{\Lambda\lambda}(\lambda) \cdot B_i(\lambda)$$
, $i = 1, 2, ..., N$

25

30

- A method according to claim 15, wherein the dye 17. comprises a first component and a second component, and further comprising the step of determining a second reference spectrum $\mathbf{A}_{02}\left(\lambda\right)$ of a second reference sample containing the dye in a second concentration with the reference spectrophotometer, and wherein the step of determining a mathematical parameter comprises the steps of
- calculating a set of vectors $\mathbf{B}_{i}\left(\lambda\right)$ from 35

.,}

$$\mathbf{B}_{i}(\lambda) = \mathbf{s}_{i1} \mathbf{A}_{1}(\lambda) + \mathbf{s}_{i2} \mathbf{A}_{2}(\lambda) + \mathbf{s}_{i3} \mathbf{A}_{0}'(\lambda)$$

in which $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$ are derived from the first and second reference spectra $\mathbf{A}_{01}(\lambda)$, $\mathbf{A}_{02}(\lambda)$ and represent spectral information about the first and second components, respectively, and i=1,2,..,N, and \mathbf{s}_{i1} , \mathbf{s}_{i2} and \mathbf{s}_{i3} are constants of selected values,

10

determining a vector $\textbf{C}_{\Delta\lambda}\left(\lambda\right)$ constituting the mathematical parameter so that

$$s_{i3} = C_{\Delta\lambda}(\lambda) \bullet B_{i}(\lambda)$$

15

20

25

30

18. A spectrophotometer comprising

a memory with a mathematical parameter for the determination of a wavelength shift $\Delta\lambda$ of the spectrophotometer, and

a processor that is connected to the memory and that is adapted to calculate the wavelength shift $\Delta\lambda$ from the mathematical parameter and from a spectrum $\boldsymbol{A}_{\!\!\!\!m}(\lambda)$ determined with the spectrophotometer on a fluid QC sample containing a dye.

19. A spectrophotometer according to claim 18, wherein the mathematical parameter constitutes a vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ fulfilling the equation

$$\Delta \lambda = \mathbf{C}_{\Lambda \lambda}(\lambda) \bullet \mathbf{A}_{m}(\lambda)$$

WO 99/66310 PCT/DK99/00313

20. A spectrophotometer according to claim 19, wherein the memory further comprises a vector $\mathbf{C_1}(\lambda)$ fulfilling the equation

$$S_1 = C_1(\lambda) \bullet A_m(\lambda)$$

and a vector $C_2(\lambda)$ fulfilling the equation

$$s_2 = C_2(\lambda) \cdot A_m(\lambda)$$

10

 $\mathbf{s_1}$ and $\mathbf{s_2}$ represent concentrations of a first and a second component, respectively, of the dye.

- 21. A spectrophotometer according to claim 20, wherein the memory further comprises predetermined constants a and b and wherein the processor is further adapted to calculate the concentration $c_{\rm est}$ of the dye according to
- $c_{est} = a s_1 + b s_2.$
 - 22. A spectrophotometer according to any of claims 18-21, for the determination of a concentration c_y of a component y of a sample and wherein the memory further comprises

at least one vector $\mathbf{A}_{int}(\lambda)$ representing spectral information of an interfering component in the sample at a concentration \mathbf{c}_{int} , and

30

25

at least one vector $\mathbf{K}_{int}(\lambda)$, and wherein

the processor is further adapted to

calculate the concentration c_{int} of the interfering component according to

$$C_{int} = K_{int}(\lambda) \cdot A_m(\lambda)$$
, and

5

if c_{int} is greater than a predetermined threshold value, c_{ref} , calculate a modified absorbance spectrum $A_{mod}(\lambda)$ according to

10
$$\mathbf{A}_{\text{mod}}(\lambda) = \mathbf{A}_{\text{m}}(\lambda) - \frac{\mathbf{C}_{\text{int}}}{\mathbf{C}_{\text{ref}}} \mathbf{A}_{\text{int}}(\lambda)$$

 $\mathbf{A}_{mod}(\lambda)$ being the modified spectrum, and

determine c_y from the modified spectrum $\mathbf{A}_{mod}\left(\lambda\right)$ according to

$$C_y = K_y(\lambda) \cdot A_{mod}(\lambda)$$

whereby the effect of interfering components on determined concentrations c_y is minimised.

- 23. A spectrophotometer according to claim 22, wherein the interfering component is fetal hemoglobin.
- 25 24. A spectrophotometer for the determination of an absorption spectrum of a fluid sample, comprising a spectral lamp for emission of light with at least one spectral line, and a processor, including a memory, that is adapted to determine the wavelength of the at least one spectral line and to compare the determined wavelength of said at least one spectral line with the assigned wavelength from an initial calibration procedure of said spectral line stored in the memory of the

WO 99/66310 PCT/DK99/00313

49

spectrophotometer, calculate a wavelength shift, and compensate the determined absorption spectrum of said sample for said wavelength shift.

- 5 25. A spectrophotometer according to claim 24, which is an oximeter, and wherein the spectral lamp emits light with at least one spectral line in the wavelength range 480-670 nm, and said oximeter is further provided with at least two photodiodes each of which convert the emitted light from the spectral lamp into a current substantially proportional to the light intensity which strikes the photodiode, and wherein the processor of said oximeter calculates the ratio F_{neon} between the two photodiode currents.
- 26. An spectrophotometer according to claim 25, wherein said spectral lamp is a neon lamp which is activated when the temperature of the spectrometer deviates more than a critical temperature difference, such as more than about 0.2-0.5°C from the previous F_{neon} measurement.




FIG. 1





FIG. 2



	Concentrations, mmol/kg water					
Component	QC level 1	QC level 2	QC level 3	QC level 4		
PIPES, Na-salt	-	-	_	64.2742		
HEPES	40.7286	31.0138	24.2665	_		
HEPES, Na-salt	20.0250	33.2875	39.6078	-		
NaCl	115.1848	82.6968	44.7194	15.9993		
KCI	2.0400	4.1068	6.1508	7.6600		
NaHCO ₃	25.348	28.38	21.9319	19.6667		
CaCl ₂ 2H ₂ O	1.2502	0.5999	0.3455	2.2201		
TRISxHCI	8.6434	14.217	7.7588	_		
TRIS	1.7789	5.2435	24.9175	_		
Sulforhodamine B,	1.0023	1.6705	2.5058	0.3444		
Na-salt						
Glucose	2.5710	6.178	15.5218	_		
Lactate, Na-salt	5.1427	1.5445	12.2997	 -		

FIG. 4




FIG. 5




FIG. 6

7/9

Level	ctHb [g/dL]	sO₂ [%]	<i>F</i> O₂Hb [%]	<i>F</i> HHb [%]	FCOHb [%]	#Met Hb [%]
1	7.80	50.00	44.50	44.50	6.00	5.00
	±0.12	±0.09	±0.26	±0.43	±0.66	±0.03
2	13.00	97.00	92.15	2.85	3.00	2.00
	±0.20	±0.62	±0.46	±0.62	±1.15	±0.07
3	19.50	70.00	49.00	21.00	20.00	10.00
	±0.29	±0.25	±0.40	±0.42	±0.78	±0.04
4	2.60	5.00	3.50	66.50	10.00	20.00
	±0.04	±0.00	±0.02	±0.29	±0.23	±0.08

FIG. 7





FIG. 8

9/9

 $F_{\text{neon,}}$ counts



λ, nm

FIG. 9




FIG. 10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 99/00313

IPC6: G01N 21/31, G01N 33/49, G01J 3/42 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC6: G01N, G01J Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE,DK,FI,NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A MO 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 3 October 1996 (03.10.96) —— A WO 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 1-26 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) —— Further documents are listed in the continuation of Box C. —— Special categories of cited documents: ** Special categories of cite	A CLASSIFI	ICATION OF SUBJECT MATTER						
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC6: G01N, G01J Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE, DK, FI, NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 3 October 1996 (03.10.96) A W0 9408225 A1 (ASLAND OIL, INC.), 14 April 1994 1-26 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) Further documents are listed in the continuation of Box C. Special categories of cited documents: """ Social categories of cited documents: """ Special categories of cited documents: """ Special categories of cited documents: """ Special categories of cited documents: """ Social categories of cited documents: """ Co	A. CLASSIFICATION OF SUBJECT MATTER							
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC6: G01N, G01J Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE, DK, FI, NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 3 October 1996 (03.10.96) A W0 9408225 A1 (ASLAND OIL, INC.), 14 April 1994 1-26 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) Further documents are listed in the continuation of Box C. Special categories of cited documents: """ Social categories of cited documents: """ Special categories of cited documents: """ Special categories of cited documents: """ Special categories of cited documents: """ Social categories of cited documents: """ Co	IPC6: G01N 21/31, G01N 33/49, G01J 3/42							
IPC6: G01N, G01J Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE,DK,FI,NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 3 October 1996 (03.10.96) A W0 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 1-26 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86)								
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SE,DK,FI,NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 3 October 1996 (03.10.96) A W0 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 1-26 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86)	Minimum docum	nentation searched (classification system followed by	classification symbols)					
SE,DK,FI,NO classes as above Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. 3 October 1996 (03.10.96) A WO 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 1-26 A WO 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 1-26 (14.04.94) A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) Further documents are listed in the continuation of Box C. X Special categories of cited documents of particular relevance to be of particular relevance to the challength of the principle or theory underlying the invention cannot be considered to browled and on or after the international filing date or print date and not inconsidered to be of particular relevance. The challength of the principle or theory underlying the invention cannot be considered to involve an inventive and the principle or theory underlying the invention cannot be special reason (as specified)	IPC6: G01	N, G01J						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A WO 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 3 October 1996 (03.10.96) A WO 9408225 A1 (ASLAND OIL, INC.), 14 April 1994 1-26 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) Further documents are listed in the continuation of Box C. * Special categories of cited documents * Cocument published after the international filing date or priori date and not in conflict with the application but cited to understand to be of particular relevance: with the published on or after the international filing date or priori date and not in conflict with the application but cited to understand to be of particular relevance: with chapting the invention consolered to be of particular relevance. * Countend published on or after the international filing date or priori date and not in conflict with the application but cited to understand to be confidered invention cannot be considered to be of particular relevance the claimed invention cannot be considered to be confidered to be confidered to be confidered to be only on the priority claim(s) or which is such as a particular relevance the claimed invention cannot be considered to be confidered to be admitted in vention cannot be considered to be confidered to be co								
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 1-26 A W0 9408225 A1 (ASLAND OIL, INC.), 14 April 1994 1-26 (14.04.94) A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 (07.01.97) A EP 0167816 A2 (ABBOTT LABORATORIES), 1-26 Further documents are listed in the continuation of Box C. * Special categories of cited documents to be only particular relevance: the claimed invention cannot be considered to be of particular relevance: the claimed invention cannot be considered invention attack of another citation or other special reason (as pecified) **Comment with may invide doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as pecified) **Comment of particular relevance: the claimed invention cannot be considered to be only provided and the province of another citation or other special reason (as pecified)	SE,DK,FI,NO classes as above							
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 1-26 3 October 1996 (03.10.96) A W0 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 1-26 (14.04.94) A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 (07.01.97) A EP 0167816 A2 (ABBOTT LABORATORIES), 1-26 Further documents are listed in the continuation of Box C. * Special categories of cited documents to be of particular relevance: the claimed invention cannot be considered to be of particular relevance: the claimed invention cannot be special reason (as specified) **Comment which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claimon or other special reason (as specified) **Comment of particular relevance: the claimed invention cannot be considered to involve an inventive and each of another claim or other special reason (as specified) **Comment of particular relevance: the claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered for center the claimed invention cannot be considered for the considered for the column of the column of the considered for the column of the considered for the column of the c	Electronic data b	base consulted during the international search (name	of data base and, where practicable, search	terms used)				
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 1-26 3 October 1996 (03.10.96) A W0 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 1-26 (14.04.94) A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 (07.01.97) A EP 0167816 A2 (ABBOTT LABORATORIES), 1-26 Further documents are listed in the continuation of Box C. * Special categories of cited documents to be of particular relevance: the claimed invention cannot be considered to be of particular relevance: the claimed invention cannot be special reason (as specified) **Comment which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claimon or other special reason (as specified) **Comment of particular relevance: the claimed invention cannot be considered to involve an inventive and each of another claim or other special reason (as specified) **Comment of particular relevance: the claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered for center the claimed invention cannot be considered for the considered for the column of the column of the considered for the column of the considered for the column of the c								
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. A W0 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 1-26 3 October 1996 (03.10.96) A W0 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 1-26 (14.04.94) A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 1-26 (07.01.97) A EP 0167816 A2 (ABBOTT LABORATORIES), 1-26 Further documents are listed in the continuation of Box C. * Special categories of cited documents to be of particular relevance: the claimed invention cannot be considered to be of particular relevance: the claimed invention cannot be special reason (as specified) **Comment which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claimon or other special reason (as specified) **Comment of particular relevance: the claimed invention cannot be considered to involve an inventive and each of another claim or other special reason (as specified) **Comment of particular relevance: the claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered to involve an inventive and each of another claimed invention cannot be considered for center the claimed invention cannot be considered for the considered for the column of the column of the considered for the column of the considered for the column of the c								
A WO 9630742 A1 (CIBA CORNING DIAGNOSTICS CORP.), 3 October 1996 (03.10.96) A WO 9408225 A1 (ASLAND OIL,INC.), 14 April 1994 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance to be of particular relevance errier document but published on or after the international filing date errier document but published on or after the international filing date errier document but published on or after the international filing date errier document but published on or after the international filing date or priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as reposited) "X" document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive special reason (as reposited) "Y" document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive special reason (as reposited) "Y" document of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive special reason (as reposited) "Ocument of particular relevance the claimed invention cannot be considered novel or cannot be considered to involve an inventive special reason (as reposited) "Ocument of particular relevance the claimed invention cannot be considered to involve an inventive special reason (as reposited)	C. DOCUME	ENTS CONSIDERED TO BE RELEVANT						
A WO 9408225 A1 (ASLAND OIL, INC.), 14 April 1994 A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) Further documents are listed in the continuation of Box C. Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance." "I" alter document but published on or after the international filing date reference are reirer document but published on or after the international filing date." "I" document of particular relevance: the claimed invention cannot be considered to establish the publication date of another otation or other special reason (as specified) "V" document of particular relevance: the claimed invention cannot be of particular relevance: the claimed invention cannot be observed to particular relevance: the claimed invention cannot be observed to particular relevance: the claimed invention cannot be observed to particular relevance: the claimed invention cannot be observed to particular relevance: the claimed invention cannot be observed."	Category* Ci	tation of document, with indication, where app	ropriate, of the relevant passages	Relevant to claim No.				
A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) Further documents are listed in the continuation of Box C. Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance: "E" erited document but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be	A W		NOSTICS CORP.),	1-26				
A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) Further documents are listed in the continuation of Box C. Special categories of cited documents A document defining the general state of the art which is not considered to be of particular relevance The document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) The document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be								
A US 5592291 A (ATSUHIRO IIDA), 7 January 1997 A EP 0167816 A2 (ABBOTT LABORATORIES), 15 January 1986 (15.01.86) * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance: "E" effic document but published on or after the international filing date of the order of the considered to the considere	A W		1-26					
Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. Special categories of cited documents "A" document defining the general state of the art which is not considered to be of particular relevance "E" erlier document but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) T" atter document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" "Ocument of particular relevance: the claimed invention cannot be document of particular relevance: the claimed invention cannot be								
Further documents are listed in the continuation of Box C. * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance to be of particular relevance "E" erlier document but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be	A U		January 1997	1-26				
Further documents are listed in the continuation of Box C. * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" erlier document but published on or after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be document of particular relevance: the claimed invention cannot be document of particular relevance: the claimed invention cannot be								
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" erlier document but published on or after the international filing date "C" later document published after the international filing date or priori date and not in conflict with the application but cited to understand the principle or theory underlying the invention the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be document of particular relevance: the claimed invention cannot be	A E	EP 0167816 A2 (ABBOTT LABORATORI 15 January 1986 (15.01.86)	1-26					
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" erlier document but published on or after the international filing date "C" later document published after the international filing date or priori date and not in conflict with the application but cited to understand the principle or theory underlying the invention the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be document of particular relevance: the claimed invention cannot be								
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be								
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be	Further documents are listed in the continuation of Roy C. V. See natest family appear							
"A" document defining the general state of the art which is not considered to be of particular relevance "E" document but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be								
"E" erlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered novel or cannot be step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be	"A" document d	defining the general state of the art which is not considered	date and not in conflict with the appli	cation but cited to understand				
special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be	"E" erlier docur	ment but published on or after the international filing date which may throw doubts on priority claim(s) or which is	"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive					
combined with one or more other such documents, such combination	special reas "O" document r means	son (as specified) elerring to an oral disclosure, use, exhibition or other	considered to involve an inventive step when the document is combined with one or more other such documents, such combination					
"P" document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family								
Date of the actual completion of the international search Date of mailing of the international search report	Date of the actual completion of the international search Date of mailing of the international search re							
1 8 -11 - 1999								
9 November 1999 Name and mailing address of the ISA/ Authorized officer	1444							
Swedish Patent Office								
Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86 Jack Hedlund Telephone No. + 46 8 782 25 00								

INTERNATIONAL SEARCH REPORT

Information on patent family members

28/09/99

International application No.

PCT/DK 99/00313

Patent document cited in search report		Publication date	Patent family member(s)			Publication date	
WO 96	30742	A1	03/10/96	AU BR CA EP JP PL US	4889096 9607917 2216657 0817957 11502927 322524 5828445	A A T A	16/10/96 09/06/98 03/10/96 14/01/98 09/03/99 02/02/98 27/10/98
NO 94	 108225	A1	14/04/94	AU AU BR DE EP JP NO	678346 2891092 9207145 69211163 0663997 8505221 951021	A A D,T A,B T	29/05/97 26/04/94 12/12/95 14/11/96 26/07/95 04/06/96 16/03/95
JS 55	92291	Α	07/01/97	EP JP	0744600 8313344		27/11/96 29/11/96
P 01	67816	A2	15/01/86	JP	61040544	A	26/02/86



PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's o	ager	nt's file reference		See Notification of Transmittal of International
P221WO			FOR FURTHER ACTION	Preliminary Examination Report (Form PCT/IPEA/416)
International	applic	cation No.	International filing date (day/monti	h/year) Priority date (day/month/year)
PCT/DK99	/003	313	10/06/1999	12/06/1998
International G01N21/3		nt Classification (IPC) or na	tional classification and IPC	
Applicant				
RADIOME	TEF	R MEDICAL A/S et al.		
and is	trans	mitted to the applicant a	according to Article 36.	d by this International Preliminary Examining Authority
2. This R	EPO	RT consists of a total of	5 sheets, including this cover s	sheet.
be (s	en a e R	mended and are the bas	sis for this report and/or sheets of the Administrative Instruct	he description, claims and/or drawings which have containing rectifications made before this Authority ions under the PCT).
				
3. This re	port ⊠		ating to the following items:	
, !!		Priority		
111		-	poinion with regard to novelty, in	eventive step and industrial applicability
IV		Lack of unity of invention		,
٧		Reasoned statement u		novelty, inventive step or industrial applicability;
VI		Certain documents cit	ed	
VII		Certain defects in the i	nternational application	
VIII	×	Certain observations o	n the international application	
Date of sub	nissio	on of the demand	Date o	f completion of this report
11/12/19	99		27.09.	2000
	exam	g address of the international	al Author	ized officer
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d			Load	es, M
		: +49 89 2399 - 4465		none No. +49.89.2399.2184



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/DK99/00313

. Bas	is of	the r	port
-------	-------	-------	------

 This report has been drawn on the basis of (substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):
 Description, pages:

	Description, pages:									
	1-42 as received on 14/09/2000 with letter of 14/09/2000									
	Claims, No.:									
1-42 as received on 14/09/2000 with letter of 14/09/2000										
	Dra	wings, sheets:								
	1/9-	9/9	as originally filed							
2.	The amendments have resulted in the cancellation of:									
		the description,	pages:							
		the claims,	Nos.:							
		the drawings,	sheets:							
3.			een established as if (some of) the beyond the disclosure as filed (F		nts had not been made	, since they have been				
4.	Ado	litional observation	s, if necessary:							

Form PCT/IPEA/409 (Boxes I-VIII, Sheet 1) (January 1994)

see separate sheet

INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

International application No. PCT/DK99/00313

- V. R asoned stat m nt und r Article 35(2) with regard to nov Ity, inventiv st p or industrial applicability; citations and explanations supporting such statement
- 1. Statement

Novelty (N)

Yes: No:

Claims 1-42

Claims

Inventive step (IS)

Yes: Claims 1-42 No:

Industrial applicability (IA)

Claims

Yes:

Claims 1-42

Claims

No:

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item I

Basis of the opinion

(The application does not appear to involve extension beyond the originally filed disclosure, for the following reasons).

Amended claim 1 seems to be based in its wording to a large extent on originally filed claim 1, with (i) an additional feature concerning the steep flank of the absorbance peak, (ii) a reference to a reference absorption spectrum $A_0(\lambda)$. The feature determining this wavelength shift from $C_{\Delta\lambda}(\lambda)$. $A_m(\lambda)$ has been omitted, being relegated to claim 3.

As far as can be seen, amendments (i) and (ii) are based on the original disclosure (i) at page 13, lines 3-5, and claim 5, and (ii) various references throughout the description concerning the wavelength shift of the absorption spectrum with respect to a reference spectrum of a reference sample containing the dye. Thus these amendments to claim 1 can be considered to be a mere limitations in scope.

The omission of feature comprising the formula can be considered NOT to represent an extension beyond the original disclosure, since original claim 18 although not a method claim, defined a concept which referred generally to a mathematical parameter and was not restricted to the parameter including the predetermined coefficient vector. This appeared in dependent claim 19, indicating it was a preferred calculation possibility to determine the wavelength shift. It is reasonable to imagine a method of equivalent scope to original claim 18, and this would have been of broader scope than original claim 1, so providing a support for the present broadening of claim 1.

Claim 21 would also appear not to represent an extension. Likewise the dependent claims seem to be substantially based on the originally field claims, except for claims 5 and 25, which seem to be based on page 6, line 14.

EXAMINATION REPORT - SEPARATE SHEET

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The invention relates to a method of quality control checking of spectrophotometer., and a spectrophotometer arranged for such checking.

Object of the invention is to improve such quality control checking..

Solution provided by the invention is as defined in claims 1 and 21, involving determining the wavelength shift of an actually measured spectrum of a quality control sample compared with a reference spectrum of said sample stored in the processor of the spectrophotometer.

Prior art documents:

D1...WO-A-9630742 deals with comparison between a current spectrum measurement and a reference one, stored in the instrument (see e.g. page 2, lines 10-25 of D1), but this involves a fitting technique which depends on intensity differences, more than a wavelength shift.

D2...WO-A-9408225 involves using one spectrophotometer to calibrate another.

D3...US-A-5592291 relates to a correction method for a spectrophotometer involving reading out data from a memory and correcting data for a target point in three dimensional space.

D4...EP-A-0167816 describes the use of operational amplifiers to correct blood monitoring information.

None of the documents disclose or seem to hint at the claimed method and apparatus.

Re Item VIII

Certain observations on the international application

Lack of clarity:

a. In claim 18, which according to the applicant relates to steps performed before those of claim 1, the references to "the spectrophotometer" at lines 30 and 34, might be mistakenly taken to refer to the "reference spectrophotometer", when they apparently refer to the spectrophotometer of claim 1. The claim should have been clarified in this respect.

Also page 9, lines 5-10 should have been corrected in this respect.

b. The passage page 7, lines 5-14, seems to repeat features which are already in the statement on page 6 corresponding to claim 1.

1 526 Rec'd PGT/PTO 12 DEC 2000

A METHOD IN QUALITY CONTROL OF A SPECTROPHOTOMETER

FIELD OF THE INVENTION

- 5 The present invention relates to a method in quality control of a spectrophotometer for monitoring performance of the spectrophotometer, such as an eximeter for measurement of blood parameters.
- 10 BACKGROUND OF THE INVENTION

Spectrophotometers for measuring the composition of a substance by absorption spectroscopy are well known. For example, oximeters are used to determine

- concentrations of various hemoglobin components or fractions in blood samples from measuring an absorption spectrum in the visible and/or infrared wavelength range. Such an oximeter is disclosed in EP 210417.
- 20 In absorption spectroscopy, determination of a spectrum of a fluid sample is performed by transmission of light through a cuvette containing a part of the sample.
- Absorption spectroscopy is based on Lambert-Beer's law according to which the absorbance determined for a sample containing a single optically active component (a dye) is directly proportional to the concentration of the component and the length of the light path through the sample in the cuvette:

30

$$A(\lambda) = \epsilon(\lambda) cd$$

(1)

in which

35 $A(\lambda)$ is the d t rmined absorbance at wavelength λ ,

- $\epsilon(\lambda)$ is the molar extinction coefficient for the component at wavelength $\lambda,$
- 5 c is the molar concentration of the component, and d is the length of the light path through the cuvette holding the sample.
- The absorbance $A(\lambda)$ of the sample is defined as the logarithm of the ratio of the light intensity before and after transmission through the sample. In practice the absorbance $A(\lambda)$ is defined as the logarithm of the ratio between the light intensity, I_0 , transmitted through a transparent aqueous reference solution and the light intensity transmitted through the sample:

$$A(\lambda) = \log \frac{I_0}{I}$$
 (2)

For samples containing more than one optically active component, the total absorbance A_{total} is the sum of the individual components' absorbances since absorbance is an additive quantity. Thus, with Y optically active components in a sample the total absorbance is given by

$$A_{total}(\lambda) = \sum_{v=1}^{\gamma} \varepsilon_{v}(\lambda) c_{v} d$$
 (3)

In a sample spectrum, the absorption $A_{total}(\lambda)$ recorded at each wavelength λ contains contributions from each of the components in the sample. The magnitude of this contribution and thereby the concentration of each component in the sample is determined according to

$$c_{y} = \sum_{j=1}^{n} K_{y}(\lambda_{j}) A_{cotal}(\lambda_{j})$$
(4)

in which

- J is the total number of wavelengths λ_j at which absorption is determined by the spectrophotometer and $K_y(\lambda_j)$ is a constant specific for component y at wavelength λ_j .
- The vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$ may be determined mathematically by using methods such as multivariate analysis, or solving n equations with n unknowns, on data from reference samples.
- It is also known to monitor performance of spectrophotometers, such as oximeters, by a measuring the absorption spectrum of a fluid quality control sample, QC sample, with the spectrophotometer in question.
- 20 Known quality control samples specific for blood analysis are typically red dye based samples designed to simulate the spectrum of blood. In addition to a red dye, they sometimes contain certain amounts of oxygen, carbon dioxide, and electrolytes at an established ph
- for determining performance of blood gas and electrolyte instruments. Synthetic QC samples having an absorption spectrum that closely mimics that of physiological blood have not yet been provided.
- Quality control of spectrophotometers, such as an eximeter, is typically performed by measuring the absorption spectrum of a QC sample comprising three to four different dyes. The dyes are mixed in a proportion so that the QC sample absorption spectrum mimics the ab-

sorption spectrum of blood. A spectrum of a QC sample is measured on the eximeter to be monitored and the parameter values determined by the eximeter are compared with predetermined control limits assigned to the QC sample by a qualified person. If the determined parameters are outside the corresponding control limits, servicing of the eximeter is required.

5

In WO 96/30742 a quality control method for monitoring performance of an oximeter is disclosed. The method comprises measuring the absorption spectrum of a QC sample and comparing it to a standard spectrum of the QC sample. Instrumental errors of the oximeter are considered to be the primary source contributing to the observed difference. Instrumental errors are converted into blood component concentration values so that instrument errors can be reported in terms understood by the operator of the instrument.

It is an important disadvantage of known quality control methods that, typically, known QC samples comprise 3-4 different dyes, causing long-term stability of the sample to be less than desired. To compensate for this, parameter value acceptance ranges in an eximeter may be widened leading to a more relaxed performance monitoring than desired.

It is another important disadvantage of known quality control methods that it is impossible with known quality control methods to distinguish between different types of instrument errors and to determine an individual contribution to deviation in parameter values from a specific type of instrument error. Thus, parameter value acceptance ranges have to be sufficiently wide to accommodate any possible type of instrument error. Fur-

ther, a quality controlled spectrophotometer cannot be diagnosed if the determined parameter values lie outside the acceptable ranges. For example, a defect spectrophotometer with a wavelength shift may introduce the same deviation in the determined parameters as seen by dilution of the QC sample.

Future spectrophotometers are expected to facilitate determination of absorption spectra with improved resolution whereby instruments of higher precision and specificity are provided. High resolution measurements of spectra makes it more difficult to develop a suitable QC sample since precision and long term stability requirements are increased.

15

20

10

5

One of the most significant errors occurring in spectrophotometers is a wavelength shift. Due to manufacturing tolerances and drift during use, each spectrophotometer positions a determined spectrum slightly differently along the wavelength axis. Therefore the wavelengths at which absorbance is determined are also positioned slightly differently for different spectrophotometers and thus, determined absorbances will vary for different spectrophotometers.

25

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a quality control method that facilitates the determination of various types of spectrophotometers errors, whereby an accurate diagnosis of an instrument failing the QC test is provided.

An instrument error affects the spectrum of a sample, and specific types of instrument errors affect the spectrum in a distinct way that may be interpreted like the presence of a component in the sample in a different concentration. For example, a variation of the length d of the light path through the cuvette causes determined absorbances A(\lambda) to vary according to Lambert-Beer's law (absorbance is proportional to d), and unintentional dilution of the sample in the cuvette affects the determined absorbance in the same way, etc.

An absorption spectrum of a sample may be defined by a vector $\mathbf{A}_{\mathbf{x}}(\lambda)$ comprising at least two elements, each of the elements representing an absorbance of the sample at a specific wavelength λ_1 .

According to a first aspect of the invention a quality control method for a spectrophotometer is provided, comprising the steps of:

20

25

15

determining with the spectrophotometer an absorption spectrum $\mathbf{A}_{\mathbf{x}}(\lambda)$ of a fluid quality control sample containing a dye selected from such dyes which provide the quality control sample with an absorption spectrum with a significant absorbance peak showing a steep flank, and

determining a wavelength shift $\Delta\lambda$ between the absorption spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ of the actually measured quality control sample and a reference absorption spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ of a reference quality control sample containing the dye stored in a memory of the spectrophotometer.

According to a preferred embodiment of the invention a method is provided, wherein the wavelength shift $\Delta\lambda$ is

determined from $\mathbf{A}_{\mathbf{z}}(\lambda)$ and a predetermined mathematical parameter stored in the memory of the spectrophotometer.

According to a further preferred embodiment of the invention a method in quality control of a spectrophotometer is provided, comprising the steps of

determining with the spectrophotometer a spectrum $\mathbf{A}_{\mathbf{m}}(\lambda)$ of a fluid QC sample containing a dye, and

determining a wavelength shift $\Delta\lambda$ from $C_{al}(\lambda) \bullet A_{al}(\lambda)$, in which $C_{al}(\lambda)$ is a predetermined coefficient vector previously stored in a memory of the spectrophotometer.

15

In a preferred embodiment of the invention a method is provided, wherein the vector $\mathbf{C}_{\Delta L}(\lambda)$ fulfils the equation

$$\Delta \lambda = C_{A\lambda}(\lambda) \bullet A_{\alpha}(\lambda) \tag{5}$$

20

25

According to a preferred embodiment of the invention the wavelength shift of a spectrophotometer is determined by forming a Taylor series of a known absorption spectrum or a reference spectrum of a certain component in a sample. After determination of an absorption spectrum of a sample comprising the component with the known absorption spectrum, the wavelength shift is determined.

In a preferred embodiment of the method according to the invention the wavelength shift $\Delta\lambda$ is determined after normalisation of the determined spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ with an estimate of the concentration of the dye.

In a further preferred embodiment of the method according to the invention $C_{al}(\lambda)$ has been determined from a combination of a reference spectrum $A_0(\lambda)$ of a reference sample containing the dye and a first derivative A_0 '(λ) of the reference spectrum.

In an approximation, only the first order derivative of the reference spectrum is considered:

$$10 \quad \mathbf{A}_{\mathbf{a}}(\lambda) = \mathbf{A}_{\mathbf{0}}(\lambda) + \Delta \lambda \, \mathbf{A}_{\mathbf{0}}^{\dagger}(\lambda) \tag{6}$$

in which $\mathbf{A}_0(\lambda)$ is the reference spectrum, $\mathbf{A}_0'(\lambda)$ is its first derivative with respect to the wavelength λ , $\Delta\lambda$ is the wavelength shift to be determined, and $\mathbf{A}_n(\lambda)$ is a spectrum of the sample with the known spectrum $\mathbf{A}_0(\lambda)$ measured by the spectrophotometer in which the wavelength shift is to be determined.

 $\Delta\lambda$ may be determined according to various mathematical methods known in the art, e.g. the equation above may be solved for a selected wavelength, the equation may be solved for a set of selected wavelengths and $\Delta\lambda$ be calculated as an average of the solutions for $\Delta\lambda$ to the equation, $\Delta\lambda$ may be determined by a least squares fit, $\Delta\lambda$ may be determined by multivariate analysis, etc.

In a preferred embodiment of the invention a method of preparing a spectrophotometer for quality control is provided, comprising the steps of

determining a first reference spectrum $\mathbf{A}_0(\lambda)$ of a reference sample containing a dye of a first concentration with a reference spectrophotometer,

AMENDED SHEET

٠,

5

30

determining a first derivative $A_0^{\;\;}(\lambda)$ of the first reference spectrum of the dye, and

determining from at least the first reference spectrum $\mathbf{A}_0(\lambda)$ and the first derivative of $\mathbf{A}_0(\lambda)$ a mathematical parameter from which a wavelength shift $\Delta\lambda$ of the spectrophotometer can be determined, and

storing the mathematical parameter in a memory of the spectrophotometer.

Preferably, the step of determining a mathematical parameter comprises the steps of

15 calculating a set of calibration vectors $\mathbf{B}_{i}\left(\lambda\right)$ according to

$$\mathbf{B}_{i}(\lambda) = \mathbf{s}_{i}\mathbf{A}_{0}(\lambda) + \mathbf{s}_{i3}\mathbf{A}_{0}(\lambda) \tag{7}$$

in which i = 1, 2, ..., N (N>1) and s_i and s_{i3} are constants of selected values,

determining a coefficient vector $C_{\Delta\lambda}(\lambda)$ constituting the mathematical parameter so that each set of corresponding values s_{13} , B_i satisfies:

$$s_{ij} = c_{ik}(\lambda) \cdot B_i(\lambda), \quad i = 1, 2, \dots, N$$
 (8)

According to a second aspect of the invention a spectrophotometer is provided comprising a processor that is adapted to determine the wavelength shift $\Delta\lambda$ between an absorption spectrum $\mathbf{A}_{\mathbf{n}}(\lambda)$ determined with the spectrophotometer on a fluid quality control sample containing a dye selected from such dyes which provide the quality control sample with an absorption spectrum with

a significant absorbance peak showing a steep flank and a reference absorption spectrum $A_0(\lambda)$ of a reference quality control sample containing the dye, stored in the memory of the spectrophotometer.

5

According to a preferred embodiment of the invention a spectrophotometer is provided comprising

a memory with a mathematical parameter for the determination of a wavelength shift $\Delta\lambda$ of the spectrophotometer, and

a processor that is connected to the memory and that is adapted to calculate the wavelength shift $\Delta\lambda$ from the mathematical parameter and from a spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ determined with the spectrophotometer on a fluid QC sample containing a dye.

According to a further preferred embodiment of the invention a spectrophotometer is provided, wherein the mathematical parameter is a coefficient vector $\mathbf{C}_{\Delta \lambda}(\lambda)$ and wherein the wavelength shift $\Delta \lambda$ is determined from $\mathbf{C}_{\Delta \lambda}(\lambda) \bullet \mathbf{A}_{\mathbf{a}}(\lambda)$.

In a preferred embodiment of the invention a spectro-photometer is provided, wherein the vector $\mathbf{C}_{\Delta \lambda}(\lambda)$ fulfils the equation

$$\Delta \lambda = C_{\Delta \lambda}(\lambda) \bullet A_{\alpha}(\lambda) \tag{5}$$

30

The mathematical parameter as mentioned above may comprise the first reference spectrum $\mathbf{A}_0(\lambda)$ and the first derivative $\mathbf{A}_0'(\lambda)$ of the first reference spectrum $\mathbf{A}_0(\lambda)$ at a selected wavelength λ_0 or at a selected set of

5

10

35

٠. :

wavelengths $\lambda_0,\ \lambda_1,\dots,\ \lambda_L,$ etc., or a parameter derived from the spectra, such as the parameter $C_{\Delta k}(\lambda)$.

Since the parameter $\Delta\lambda$ is proportional to a total concentration c_{qc} of the dye, $\Delta\lambda$ is typically normalised with c_{qc} or an approximation to c_{qc} , e.g. when the dye is a two-component dye, such as Sulforhodamine B, $\Delta\lambda$ is preferably normalised with a concentration of a first component of the dye s_1 . The normalisation of $\Delta\lambda$ with s_1 is desirable when there is a difference between the concentration of the dye in a reference sample from which the reference spectrum was determined, and the concentration of the dye in the QC sample.

- Thus, in a preferred embodiment of the spectrophotometer according to the invention, the mathematical parameter stored in the memory constitutes a vector $\mathbf{C}_{\Delta \lambda}(\lambda)$ from which the wavelength shift $\Delta \lambda$ may be determined.
- 20 According to a further preferred embodiment of the invention, the QC sample comprises a dye with two components in a chemical equilibrium where the ratio between the concentration of each component varies with the total concentration of the dye. In this case the shape of the absorption spectrum is dependent on the total concentration of the dye. This characteristic of the dye makes it possible to distinguish between a concentration measurement error caused by undesired dilution of the sample in the cuvette, and a measurement error caused by light path changes in the cuvette.

Thus, the method of preparing a spectrophotometer for quality control may comprise determining a first reference spectrum $A_{01}(\lambda)$ of a reference sample containing the dye in a first concentration and determining a sec-

ond reference spectrum $A_{02}(\lambda)$ of a reference sample containing the dye in a second concentration with the reference spectrophotometer, the dye comprising a first component and a second component in chemical equilib-5 rium. Mathematically two model spectra $A_1(\lambda)$ and $A_2(\lambda)$ that represent spectral information about the first and the second component, respectively, may be derived from the first and second reference spectra $A_{01}(\lambda)$ and $A_{02}(\lambda)$ in such a way that the spectra of the reference samples can be calculated as a weighted sum of $A_1(\lambda)$ and $A_2(\lambda)$. 10 For example, $A_1(\lambda)$ and $A_2(\lambda)$ may be the individual spectra from the two components, respectively, of the dye, or, $A_1(\lambda)$ may be the sum of the individual spectra from the two components while $A_2(\lambda)$ may be the difference between the individual spectra of the two compo-15 nents, etc. Preferably, $A_1(\lambda)$ and $A_2(\lambda)$ are determined from reference spectra $A_{01}(\lambda)$ and $A_{02}(\lambda)$ by Principal Components Analysis (PCA).

20 The spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ determined by the spectrophotometer is then given by

$$\mathbf{A}_{m}(\lambda) = \mathbf{S}_{1}\mathbf{A}_{1}(\lambda) + \mathbf{S}_{2}\mathbf{A}_{2}(\lambda) + \Delta\lambda \mathbf{A}_{0}'(\lambda)$$
 (9)

25 Each of the parameters s_1 , s_2 , and $\Delta\lambda$ may be determined by mathematical methods, such as multivariate analysis on data obtained from reference samples.

In a preferred embodiment of the invention, the step of determining a mathematical parameter may comprise the steps of

calculating a set of vectors $\mathbf{B}_{i}(\lambda)$ from

35
$$\mathbf{B}_{i}(\lambda) = \mathbf{s}_{i1} \mathbf{A}_{1}(\lambda) + \mathbf{s}_{i2} \mathbf{A}_{2}(\lambda) + \mathbf{s}_{i3} \mathbf{A}_{0}'(\lambda)$$
 (10)

in which $i=1,\ 2,\ldots,\ N\ (N>1)$ and $s_{i1},\ s_{i2}$ and s_{i3} are constants of selected values,

determining a vector $\mathbf{C}_{\Delta \lambda}(\lambda)$ constituting the mathematical parameter so that

$$\mathbf{S}_{i3} = \mathbf{C}_{\Delta i}(\lambda) \bullet \mathbf{B}_{i}(\lambda), \qquad i = 1, 2, \dots, N \tag{11}$$

Further, the mathematical parameter may comprise a vector $\mathbf{C}_1(\lambda)$ fulfilling that

$$s_{i1} = C_i(\lambda) \bullet B_i(\lambda), \qquad i = 1, 2, \dots, N$$
 (12)

and still further, the mathematical parameter may also comprise a vector $C_2(\lambda)$ fulfilling that

$$\mathbf{s}_{i2} = \mathbf{C}_{2}(\lambda) \bullet \mathbf{B}_{i}(\lambda), \qquad i = 1, 2, \dots, N$$
 (13)

According to a preferred embodiment of the invention, the method in quality control of a spectrophotometer may utilise a QC sample containing the dye in a known concentration cqc and comprising the first and second components, and may further comprise the steps of

calculating parameters s1 and s2 from

$$S_1 = C_1(\lambda) \bullet A_n(\lambda) \tag{14}$$

30
$$s_2 = C_2(\lambda) \cdot A_n(\lambda)$$
 (15)

in which $C_1(\lambda)$ and $C_2(\lambda)$ are the predetermined vectors previously stored in the memory of the spectrophotometer, and

35

25

5

10

15

20

25

3 C

35

calculating an estimated concentration c_{est} of the dye from

$$C_{est} = a S_1 + b S_2$$
 (16)

in which a and b are predetermined constants previously stored in the memory of the spectrophotometer, and s_1 and s_2 represents concentrations of a first and a second component, respectively, of the dye.

Likewise, in a preferred embodiment of the invention the memory of the spectrophotometer may further comprise vectors $C_1(\lambda)$ and $C_2(\lambda)$ fulfilling the equations (14) and (15).

The memory may also comprise predetermined constants a and b and the processor may be further adapted to calculate the concentration cest of the dye according to equation (16)

$$c_{est} = a s_1 + b s_2$$
 (16)

It is preferred that the dye has a spectrum with a significant absorbance peak with a steep flank within the measurement range of the spectrophotometer in order to accurately determine small wavelength shifts. For example, when the sample to be analysed is blood, a wavelength shift of 0.05 nm is sufficient to cause an inaccurate determination of several blood parameters, such as ctHb, sO₂, FO₂Hb, FHHb, FCOHb, FMetHb, etc.

Further, it is preferred that the spectrum of the QC sample resembles spectra of samples, which the spectrophotometer in question is intended to analyse so that performance of the instrument can be monitored.

For example, in blood analysis important blood components have significant absorbances in the wavelength range from 480 to 670 nm. Thus, a dye with a spectrum resembling a blood spectrum and having a significant absorbance peak in the range from 400 to 800 nm, preferably from 480 to 670 nm, and having a steep absorbance flank, such as a flank having steepness larger than 40 mAbs/nm, preferably larger than 50 mAbs/nm for a light path length of 100 µm, is preferred for use in the methods according to the present invention. The dye should, preferably, also have a molar extinction coefficient in the range from 10,000 to 100,000.

- The dye may belong to one of several chemical classes, such as cyanine dyes, azacyanine dyes, triarylmethine dyes, acridine dyes, azine dyes, oxazine dyes, thiazine dyes, xanthene dyes, etc. Dyes belonging to the first four classes are typically cationic dyes being water soluble due to the molecule's positive charge. The xanthene dyes include the cationic and neutral rhodamines and the anionic sulforhodamines among which Sulforhodamine B is a preferred dye.
- According to a preferred embodiment of the invention, the spectrum of reference samples containing the dye in at least two different concentrations is determined, e.g. by an accurate reference instrument of the same type as the spectrophotometer to be quality controlled, at a selected set of wavelengths. Then the coefficient vectors C₁(λ), C₂(λ) and C_{A1}(λ) and the constants a and b are determined, e.g. by multivariate analysis, and stored at the time of manufacture in the memory of the spectrophotometers to be quality controlled by fluid QC samples when put into their normal use.

5

10

15

25

30

35

Vantameret men.

On manufacture of a QC sample the concentration c_{qc} , the ratio s_z/s_1 denoted Q_{ref} and an initial wavelength shift $\Delta\lambda_{qc}$ may be determined by a reference spectrophotometer. The initial wavelength shift of the QC sample emerges mainly from a variation in the composition of the solvent of the dye in the QC sample.

A label, such as a bar-code label, a magnetic label, etc. may be attached to each of the QC samples containing one or more of the values $c_{\rm QC}$, $Q_{\rm ref}$ and $\Delta\lambda_{\rm qc}$ in question. Alternatively one or more of the values may be printed in a bar code on a paper sheet following a set of QC samples. The values appearing on the labels or paper sheet are designated assigned values.

During quality control of a specific spectrophotometer, the assigned values of c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ are read by the spectrophotometer and the values are stored in its memory. Then the spectrum of the QC sample is determined and s_1 , s_2 , and $\Delta\lambda$ are determined as previously described. The determined values for $Q_{est} = s_2/s_1$, $\Delta\lambda$ and c_{est} are also calculated and compared to the assigned values of Q_{ref} , $\Delta\lambda_{qc}$ and c_{qc} , respectively.

A possible dilution of the QC sample may be determined from a difference between $Q_{\rm est}$ and $Q_{\rm ref}$, and the combined effect of dilution and deviations in length d of the light path through the cuvette may be determined from a difference between $c_{\rm est}$ and $c_{\rm qc}$.

The estimated parameter values, such as $\Delta\lambda$, c_{est} , and Q_{est} , may be used for determination of parameter values of samples, the analysis of which the spectrophotometer is intended for, so that the outcome of the quality

14 UB UB 10.12 rad -40 00212100

control procedure can be reported by the instrument in quantities meaningful for an operator of the instrument.

- 5 For example, in an oximater for determination of blood parameter values, the theoretical modifications to one or several predetermined standard blood spectra caused by a measurement error corresponding to one of the parameters Δλ, c_{est}, and Q_{est} determined in the quality control procedure may be calculated by the oximeter. From the modified spectra, the oximeter may calculate corresponding blood parameter values to be reported to the operator of the instrument.
- The predetermined standard blood spectra may either be stored in the memory of the oximeter, or they may be derived mathematically by the processor in the oximeter from predetermined spectra of each blood component comprised in the standard blood samples.

In a preferred embodiment of the invention predetermined control limits for the reported blood parameter values are printed on a sheet of paper following a set of QC samples. The operator may compare blood parameter values reported by the oximeter with the predetermined control limits on the paper sheet, and determine whether the reported values are within the control limits.

The predetermined control limits may also be stored in a label of the QC sample which label is read by the oximeter so that the oximeter is adapted to perform the comparison between the reported blood parameter values and the corresponding control limits.

20

25

5

25

30

35

Radiometer men.

In a preferred embodiment of the invention, a method for repressing absorption spectra of interfering components or substances in a fluid sample, is also provided.

In the present context an interfering component in a sample is a component other than the preselected components for which the spectrophotometer is adapted to report parameter values, and the presence of said interfering component in the sample may interfere with the absorption spectrum of at least one of said preselected components.

In a determined sample spectrum, the absorbance $\mathbf{A}_{\mathbf{m}}(\lambda)$ recorded at each wavelength λ contains contributions from each of the components in the sample including said interfering components. The magnitude of the contribution and thereby the concentration of each component in the sample is determined according to equation (17) or equation (18) below

$$c_{y} = \sum_{j=1}^{J} K_{y} (\lambda_{j}) A_{n} (\lambda_{j})$$
(17)

or the equivalent form

$$c_{y} = K_{y}(\lambda) \cdot A_{m}(\lambda) \tag{18}$$

The vectors $\mathbf{K}_{\mathbf{Y}}(\lambda)$ may be determined mathematically by using methods, such as multivariate data analysis, or solving n equations with n unknowns from data obtained from reference samples. By including one or several interfering components or substances in the reference sample, of which the reference spectrum is determined, one or several of the vectors $\mathbf{K}_{\mathbf{Y}}(\lambda)$ corresponding to one or several of the interf ring components may be de-

14,00 00 10.1- 100 -47 Juliano

5

20

25

termined. The vector or vectors $K_y(\lambda)$ corresponding to the interfering components are generally designated $K_{int}(\lambda)$ and stored in the memory of the spectrophotometer together with the vectors $K_y(\lambda)$.

The spectrophotometer may further provide one or several predetermined vectors, $\mathbf{A}_{int}(\lambda)$, representing spectral information of the interfering components. Each $\mathbf{A}_{int}(\lambda)$ is obtained at a reference concentration \mathbf{c}_{ref} , whereby the spectrum of any interfering component may be derived at the determined concentration of the component according to Lambert-Beer's law, equation (1).

In this preferred embodiment of the invention, the effect of the interfering components on determined blood parameter values is minimised by following a three stage process, in the following denoted "repression of spectra of interfering components".

First stage is to determine the concentration of interfering components in the sample. Second stage is to determine a modified spectrum of the sample by subtracting the spectrum of the interfering component of the determined concentration from the measured spectrum $\mathbf{A}_{\mathbf{m}}(\lambda)$ of the sample. Third stage is to determine concentrations of blood components $\mathbf{c}_{\mathbf{y}}$ and parameter values of blood components from the modified spectrum.

According to this preferred embodiment of the invention, a spectrophotometer with repression of spectra of interfering components in a fluid sample is provided, for determination of a concentration cy of a component y of a sample and wherein the memory further comprises

at least one vector $\mathbf{A}_{int}(\lambda)$ representing spectral information of an interfering component in the sample at a concentration \mathbf{c}_{ref} , and

5 at least one vector $K_{int}(\lambda)$, and wherein

THE DOLL OF THE THE STREET

the processor is further adapted to

calculate the concentration c_{int} of the interfering component according to

$$c_{int} = K_{int}(\lambda) \bullet A_{n}(\lambda)$$
 (19)

and if c_{int} is greater than a predetermined threshold value, c_{ref} , modify the measured spectrum $A_{mod}(\lambda)$ according to

$$\mathbf{A}_{\text{mod}} \left(\lambda \right) = \mathbf{A}_{\mathbf{a}} \left(\lambda \right) - \frac{c_{\text{int}}}{c_{\text{ref}}} \mathbf{A}_{\text{int}} \left(\lambda \right)$$
 (20)

20 $\mathbf{A}_{mod}(\lambda)$ being the modified spectrum, and

determine c_y from the modified spectrum $A_{mod}\left(\lambda\right)$ according to

25
$$c_y = K_y(\lambda) \cdot A_{mod}(\lambda)$$
 (21)

whereby the effect of interfering components on determined concentrations c_y is minimised.

The measured spectrum is only modified if the determined concentration of the interfering component is above a predetermined threshold value. This is because the modification of the measured spectrum creates some undesired "process noise" in the modified spectrum, due to an uncertainty in the estimate of the spectrum of

the interfering component. This addition of "process noise" in the modified spectrum is only justified when the concentration of the interfering component in the sample is larger than the threshold value.

5

10

15

An oximeter for blood analysis may provide several predetermined vectors for interfering components or substances of clinical importance and provide corresponding values of the vectors $\mathbf{K}_{int}(\lambda)$ in the memory. The interfering components may be chosen among components, which have previously caused significant interference in oximetry measurements, such as Fetal Hemoglobin, Bilirubin, Cardio Green, Evans Blue, Methylene Blue, Intralipid, HiCN, SHb, etc. By repressing the spectra of these components an oximeter with better precision in measurement of blood parameter values than currently available instruments is provided.

BRIEF DESCRIPTION OF THE DRAWINGS

20

30

The invention will now be described with reference to the drawings, wherein

- Fig. 1 is a block diagram of an oximeter according to the invention,
 - Fig. 2 is a schematic diagram of a wet section of an oximeter according to the invention,
 - Fig. 3 shows main components of a spectrometer, i.e. the optical part of an oximeter according to the invention,
 - Fig. 4 shows compositions of QC samples levels 1-4.
 - Fig. 5 shows absorption spectra of Sulforhodamine B in three concentrations,

Fig. 6 shows two normalised model spectra determined with Principal Component Analysis from Sulforhodamine B.

Fig. 7 is a table comprising parameter values of blood samples each related to one of QC sample levels 1-4, Fig. 8 shows absorption spectra of four standard blood samples related to quality control levels 1-4, Fig. 9 is a graph of a variable Fneon plotted against the wavelength of light striking two photodiodes in the spectrometer,

Fig. 10 shows response curves of photodiodes located in wavelength channels 70, 71 and 72.

DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT

15

Fig. 1 is a block diagram comprising a spectrometer 1 in an oximetry module (not shown) connected to a printed circuit board 2 with a data cable 6 comprising electrical conductors. The printed circuit board 2 controls and collects data from the spectrometer 1. The

- trols and collects data from the spectrometer 1. The data collected are transmitted to a data processing unit 3 comprising a memory (not shown) and a processor (not shown). Values of predetermined coefficient vectors $C_1(\lambda)$, $C_2(\lambda)$ and $C_{\Delta \lambda}(\lambda)$ are stored in the memory. A
- barcode reader 5 is adapted to read data from bar-code labels mounted on QC samples or on a paper sheet enclosed with a set of samples, and transmits data to the data processing unit 3 via a data management computer 7. A power supply module 4 supplies power to the oximetry module from a mains connection.
- Fig. 2 is a schematic diagram of a wet section of an eximeter according to the invention, wherein a blood sample (not shown) is entered into the exim ter through an inlet probe 20. The sample is transferred to a cu-

vette 74. A preheater 15 is positioned along the sample path 30 to heat the sample to a substantially constant temperature of 37 °C. Pumps 10 are used to pump liquids and gasses through the wet section.

5

10

15

20

Fig. 3 shows the main components of the spectrometer 1, wherein a light beam 75 with constant intensity is transmitted from a halogen lamp 70 to the cuvette 74 which comprises the blood or QC sample and is included in a hemolyzer 79. The blood sample is hemolyzed by means of ultrasonic waves. Hemolyzing is a process, which ruptures the walls of the red blood cells in the sample, thereby making the blood cells release their content of hemoglobin. The light beam 75 is transmitted to the cuvette 74 through an infrared filter 71, and a biconvex lens 72. After passing through the cuvette 74, the light beam 75 is transmitted to a measurement section 76, by means of an optical fibre 77. The light beam 75 passes through a thin slit 78, whereby the beam 75 is directed towards a concave grating unit 80, diffracting the light beam 75 according to wavelength.

The concave grating unit 80 focuses light on a photodiode array 83, to which a diffracted light beam 82 is 25 transmitted. The photodiode array 83 may consist of 128 photodiodes, and the array 83 is arranged in such a manner that light comprising a range of wavelengths of approximately 1.5 nm in the diffracted light beam 82, strikes a photodicde (not shown), which converts the light into a current substantially proportional to the 30 light intensity which strikes it. By measuring the value of the current in each of the 128 photodiodes of the photodiode array 83, a discrete intensity spectrum of the light beam 82 after transmission through the sample is produced. From this intensity spectrum an ab-35

sorption spectrum of the blood sample comprised in the cuvette 74 may be determined by the oximeter.

The absorption spectrum is measured in 128 channels located in the wavelength range 478-672 nm in the preferred embodiment of the invention. A channel is, in the present context, the part of the spectrum which is transmitted to a particular photodiode in the diode array 83.

10

15

20

35

5

According to the invention a wavelength shift of the oximeter is determined in the quality control procedure. It is preferred that four different types of quality control samples (QC samples levels 1-4) are provided, cf. Fig. 4. The QC levels comprise Sulforhodamine B in different concentrations. Increased reliability in the quality control of the oximeter is provided by measuring the absorption spectrum of QC samples at several QC levels. By utilising QC samples comprising Sulforhodamine B in different concentrations, it is ensured that the oximeter measures blood parameters correctly over a wide range of component concentrations in blood samples.

In solution Sulforhodamine B shows long term stability. The steep absorbance flank allows an accurate determination of the wavelength shift of the oximeter, since even very small wavelength shifts produce a large change in the measured absorbance at a given wavelength of a Sulforhodamine B containing sample.

In aqueous solution Sulforhodamine B is a dye with two components in a chemical equilibrium where the ratio between the concentration of each component in the dye varies with the total concentration of the dye. In this

case the shap of the absorption spectrum is dependent on the total concentration c_1 of the dye. This may be seen in Fig. 5, which shows three absorption spectra $A_{01}(\lambda)$ 110, $A_{02}(\lambda)$ 111 and $A_{03}(\lambda)$ 112 of Sulforhodamine B samples determined at the total concentrations 2.5058 mmol/kg, 1.6705 mmol/kg and 1.0023 mmol/kg, respectively. The Sulforhodamine B samples correspond to QC levels 1-3 as shown in Fig. 4.

- Mathematically, two model spectra $\mathbf{A}_1(\lambda)$ 105 and $\mathbf{A}_2(\lambda)$ 106 as shown in Fig. 6 may be derived from at least two reference spectra, e.g. $\mathbf{A}_{01}(\lambda)$ 110 and $\mathbf{A}_{02}(\lambda)$ 111 of Fig. 5, wherein the two model spectra represent spectral information about a first and a second component, respectively of Sulforhodamine B, in such a way that the spectrum of the dye can be calculated as a weighted sum of $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$.
- The two model spectra are, preferably, determined by Principal Component Analysis (PCA), whereby two orthogonal vectors are determined constituting the mathematical model spectra, $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$. A set of scores or parameters \mathbf{s}_{i1} and \mathbf{s}_{i2} is also provided by the PCA analysis for each concentration of the dye, as the spectrum of the dye at a concentration \mathbf{c}_i can be calculated as a weighted sum of model spectra $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$ and their corresponding scores or weights \mathbf{s}_{i1} and \mathbf{s}_{i2} .
- The PCA analysis may be provided by several computer programs, which are commercially available. The program used in the present embodiment is the "Unscrambler". The two model spectra $\mathbf{A}_1(\lambda)$ 105 and $\mathbf{A}_2(\lambda)$ 106 shown in Fig. 6 are determined by PCA from the three reference spectra $\mathbf{A}_{01}(\lambda)$, $\mathbf{A}_{02}(\lambda)$ and $\mathbf{A}_{03}(\lambda)$ with "Unscrambler".

The reference concentrations of the dye in the solution at which the reference absorption spectra $A_{01}(\lambda)$, $A_{02}(\lambda)$ and $A_{01}(\lambda)$ are measured, are determined from the weight of the dye, Sulforhodamine B in powder form and the volume of the solvent. The reference absorption spectra are determined by measuring the absorption spectra of 5 samples containing Sulforhodamine B at each reference concentration, and determining an average value for the reference spectrum for each concentration. The reference absorption spectra of the samples are measured by a reference oximeter, which by definition has a zero wavelength shift.

- In practice, an oximeter not specifically appointed and handled as a reference oximeter will always exhibit some wavelength shift Δλ whereby a measured absorption spectrum A_m(λ) of a sample will differ slightly from the reference spectrum A₀(λ) of the same sample measured on the reference oximeter. The relationship between the measured spectrum A_m(λ) and a reference spectrum A₀(λ) and the model spectra is for small wavelength shifts
 - 25 $\mathbf{A}_{\mathbf{x}}(\lambda) = \mathbf{S}_1 \mathbf{A}_1(\lambda) + \mathbf{S}_2 \mathbf{A}_2(\lambda) + \Delta \lambda \mathbf{A}_0'(\lambda)$

according to equation (9)

wherein $\Delta\lambda$ $A_0'(\lambda)$ is the first term in a Taylor series of the reference spectrum $A_0(\lambda)$.

The first derivative of the reference spectrum $\mathbf{A_0}^{\bullet}(\lambda)$ is preferably calculated in approximation as a first derivative of the model spectrum $\mathbf{A_1}^{\bullet}(\lambda)$. The approximation is justified since the values of the scores $\mathbf{s_{i1}}$ for the model spectra $\mathbf{A_i}(\lambda)$ are found to be much higher than the

values of the scores s_{i2} for the model spectra $\mathbf{A}_{2}\left(\lambda\right)$, of Sulforhodamine B in relevant concentrations c_{i} , so that

$$\mathbf{A}_{0}^{\dagger}(\lambda) = \mathbf{S}_{1}\mathbf{\bar{A}}_{1}^{\dagger}(\lambda) + \mathbf{S}_{2}\mathbf{\bar{A}}_{2}^{\dagger}(\lambda) \approx \mathbf{S}_{1}\mathbf{\bar{A}}_{1}^{\dagger}(\lambda) \tag{22}$$

5

whereby the measured spectrum $\textbf{A}_{ni}\left(\boldsymbol{\lambda}\right)$ may be approximated by

$$\mathbf{A}_{ai}(\lambda) = \mathbf{s}_{i1}\mathbf{A}_{1}(\lambda) + \mathbf{s}_{i2}\mathbf{A}_{2}(\lambda) + \Delta\lambda_{i}\mathbf{s}_{i1} \mathbf{A}_{i}(\lambda)$$
 (23)

10

 $\Delta \lambda_i s_{i1}$, s_{i1} , s_{i2} are the scores or the constants corresponding to a concentration c_i .

Coefficient vectors $C_1(\lambda)$, $C_2(\lambda)$ and $C_{\lambda\lambda}(\lambda)$ are, preferably, determined by multivariate analysis from the scores and the corresponding determined absorption spectra.

The multivariate analysis starts by generating a table with 64 rows and 4 columns. The first three columns in this table comprise selected values of either one of the scores $\Delta\lambda_{i}s_{i1}$, s_{i1} , s_{i2} , and the last column comprises the corresponding calculated value of the spectrum $\mathbf{A}_{ai}(\lambda)$. Each row constitutes a calibration vector, and the entire table constitutes 64 calibration vectors.

25

20

The 64 values of each score appearing in one and the same column are evenly distributed between:

0 and
$$\frac{1}{\sqrt{A^2(\lambda_i)}}$$

wherein $A^2(\lambda_j)$ denotes the summation of squared absorbances across 128 wavelengths of the particular spectrum that corresponds to a particular score; i.e. the values of the score s_{i1} are evenly distributed between 0 and reciprocal of (square root($A_i^2(\lambda)$).

The next step in the multivariate analysis comprises to determine from the table the coefficient vector $C_1(\lambda)$ by Principal Component Regression so that each set of scores s_{11} , and the corresponding spectrum $\lambda_{mi}(\lambda)$, satisfies

$$s_{i1} = C_1(\lambda) \bullet A_{i\lambda}(\lambda) \tag{24}$$

10 From the table the coefficient vector $\mathbf{C}_2(\lambda)$ is determined by Principal Component Regression so that each set of scores \mathbf{s}_{12} and the corresponding spectrum $\mathbf{A}_{n1}(\lambda)$, satisfies

15
$$s_{i2} = C_2(\lambda) \cdot A_{mi}(\lambda)$$
 (25)

20

From the table the coefficient vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ is determined by Frincipal Component Regression (PCR) so that each set of scores $\Delta\lambda_i s_{i1}$ and the corresponding spectra $\mathbf{A}_{ni}(\lambda)$, satisfies

$$\Delta \lambda_{i} \ s_{il} = C_{\lambda i}(\lambda) \ \bullet \ A_{ni}(\lambda) \tag{26}$$

Further, it is assumed that the following relation

25 between the calculated scores and a total concentration,
ci of the dye exists

$$c_i = a s_{i1} + b s_{i2}$$
 (27)

wherein constants a and b may be found by several methods, preferably, by inserting the determined scores from the total concentrations, ci of the dye of concentrations 2.5058 mmol/kg and 1.0023 mmol/kg in equation (27) and solve the resulting two equations with two unknown quantiti s, for a and b. The determined values of

a, b are: a=0.1425; b=0.0931, so that equation (27) is determined as

$$c_i = 0.1425 \ s_{i1} + 0.0931 \ s_{i2}$$
 (28)

5

10

The validity of equation (28) may be checked by inserting scores s_{i1} , s_{i2} from reference solutions with total concentrations c_i of Sulforhodamine B not used in the determination of a and b. Thereby, the validity of equation (28) has been confirmed experimentally.

In field use of the spectrophotometer the coefficient vectors are applied as follows:

From the coefficient vector, $C_1(\lambda)$ a score or parameter value, s_1 may be determined according to equation (14)

$$s_1 = C_1(\lambda) \bullet A_n(\lambda)$$

wherein $\mathbf{A}_{\mathbf{m}}(\lambda)$ is a measured spectrum of a QC/reference sample.

From the coefficient vector, $C_2(\lambda)$ a score or parameter value, s_2 may be determined according to equation (15)

25

$$s_2 = C_2(\lambda) \bullet A_m(\lambda)$$

wherein $\mathbf{A}_{\mathbf{n}}(\lambda)$ is a measured spectrum of a QC/reference sample.

30

From the coefficient vector $\mathbf{C}_{\Delta L}(\lambda)$ a score or parameter value $\Delta \lambda s_1$, which is proportional to the wavelength shift may be determined according to

35
$$\Delta \lambda s_1 = \mathbf{C}_{\Delta \lambda}(\lambda) \mathbf{A}_{\mathbf{m}}(\lambda)$$
 (29)

wherein $A_n(\lambda)$ is a QC/reference sample.

Determined s_1 , s_2 scores may be interpreted as the equivalent concentrations of the first and the second component of the dye, respectively. The first component corresponds to the mathematical model spectrum $\mathbf{A}_1(\lambda)$, and the second component corresponds to the mathematical model spectrum $\mathbf{A}_2(\lambda)$.

10

15

20

30

5

The determined coefficient vectors $\mathbf{C}_{\Delta L}(\lambda)$, $\mathbf{C}_{\Delta}(\lambda)$ and $\mathbf{C}_{2}(\lambda)$ are stored in a matrix in the memory of the oximeter at the time of manufacture. The determined constants a, b are also stored in the memory of the oximeter at the time of manufacture.

QC samples are, preferably, manufactured in lots, which may comprise 40,000-50,000 samples. The lot values of c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ are, preferably, determined during manufacturing by measuring 5-10 samples on 3 reference oximeters. The oximeters have been adjusted to report exact parameter values on a standard blood sample.

Average values of each of the measured parameters c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ are calculated and preferably stored on a bar-code label attached to each of the QC samples.

During a quality control procedure of an oximeter in normal operation, e.g. at a hospital, the values of c_{qc} , Q_{ref} and $\Delta\lambda_{qc}$ are read from the bar-code label of the QC sample by a bar-code reader and stored in the memory of the oximeter.

Then the absorption spectrum of the QC sample is deter-35 mined. An estimated concentration of Sulforhodamine B in the QC sample may be determined by the measured absorption spectrum $\mathbf{A}_m(\lambda)$ by equation (27) as

 $c_{est} = 0.1425 s_1 + 0.0931 s_2$

5

since the values of s_1 and s_2 can be determined by the measured absorption spectrum $\mathbf{A}_{\mathbf{c}}(\lambda)$ and the vectors $\mathbf{C}_1(\lambda)$ and $\mathbf{C}_2(\lambda)$ according to equations (14) and (15). The ratio between s_1 and s_2 is determined and denoted Q_{est} .

10

An estimate of a score proportional to the wavelength shift of the oximeter is provided by equation (26)

$$\Delta \lambda s_1 = C_{\Delta \lambda}(\lambda) \cdot A_m(\lambda)$$
.

15

25

30

Since the value of s_1 has been determined, the value of the wavelength shift of the oximeter is determined by dividing the score $\Delta\lambda$ s_1 with s_1

$$20 \Delta \lambda = \frac{C_{\Delta \lambda} (\lambda) \cdot A_{\alpha}(\lambda)}{s_1} (30)$$

The length of the cuvette light path d_0 in the eximeter is, preferably, determined by measuring an absorption spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ of a Sulforhodamine B reference solution. The concentration of Sulforhodamine B, c_{ref} , is, preferably, provided as an assigned value.

To determine the value of d_0 , the absorption spectrum $\mathbf{A}_m(\lambda)$ of the reference solution is measured, and an estimate of the concentration \mathbf{c}_{000} of the dya is calculated by the processor in the eximeter according to equations (27), (14), (15) by utilising predetermined coefficient vectors $\mathbf{C}_{\Delta 1}(\lambda)$, $\mathbf{C}_{1}(\lambda)$ and $\mathbf{C}_{2}(\lambda)$ and con-

stants a, b stored in the memory of the oximeter as previously described.

The concentration c_{est} of the reference solution determined by the eximeter is utilised to calculate an actual value of the cuvette light path length, d_0 , in the eximeter according to

$$d_0 = d_{ref} \frac{C_{est}}{C_{ref}}$$
 (31)

10

5

wherein d_{ref} is a reference value of the cuvette light path length, which is previously stored in the memory of the oximeter. The calculated value of d_0 is subsequently stored in the memory of the oximeter.

15

20

25

The difference between the value of $\Delta\lambda$ determined for the Sulforhodamine B reference solution and the assigned value $\Delta\lambda_{rer}$ for the reference solution is utilised to shift the subsequently measured spectra along the wavelength axis.

The absorbance $A(\lambda)$ of a fluid sample is measured by the eximeter by determining the logarithm of a light intensity I_0 transmitted through a transparent aqueous reference solution divided by the light intensity I transmitted through the fluid sample in question, according to equation (2)

$$A(\lambda) = \log \frac{I_0}{I}.$$

30

Is is denoted the zero point intensity, and is measured automatically at every calibration of the oximeter with said reference solution.

During a quality control of the oximeter, a determined value of $c_{\rm ext}$ may be compared with the corresponding value $c_{\rm qc}$ read from the label of the QC sample. A difference between the values may originate from two of the variables in Lambert-Beer's law, equation (1)

 $A(\lambda) = \varepsilon(\lambda) c d$

It applies that either the cuvette light path length d in the oximeter is different from the do value stored in the memory of the oximeter, which causes a higher or a lower value of the measured absorbance, or the measured concentration cost of the dye deviates from the value of coc.

15

35

5

The determined concentration c_{est} may deviate from the value of c_{qc} due to errors in the wet section of the oximeter, such as defect tubes, defect pumps, errors in the cuvette, etc. It may all lead to undesired dilution of the sample. However c_{est} may also be different from c_{qc} due to an incorrect light path length d_0 of the cuvette.

If there is a difference between c_{est} and c_{qc}, and the value of C_{ref} being equal to Q_{est}, the difference between the estimated concentration and the reference concentration values may be caused by a difference between the light path length d₀ of the cuvette as calculated during calibration and the reference value d_{ref} of the length determined during manufacture.

If there is a difference between $c_{\rm est}$ and $c_{\rm qc}$, the value of $Q_{\rm ref}$ being different from $Q_{\rm est}$, the sample may be diluted. A dilution causes the concentration of the dye to be smaller than $c_{\rm ref}$ and further causes a shift in

the chemical equilibrium between the components s_1 and s_2 which causes the value of Q_{est} to deviate from Q_{ref} .

The determined differences between measured parameters $\Delta\lambda,~c_{\text{\tiny est}},~\text{and}~Q_{\text{\tiny est}}$ and the corresponding parameters read 5 from the bar-code label of the QC sample may be reported by the oximeter to the operator e.g. by means of a printer. A printed message may comprise information as to which of the measured parameters caused the QC sample to fail the quality control. Together with a 10 printout of the failing parameter a message suggesting which part of the oximeter needs repair or service, may be included. For example, the printed message may recommend a repair of the measurement section 76 of the 15 spectrometer 1, if the measured wavelength shift $\Delta\lambda$ is larger than a predetermined threshold value stored in the memory of the oximeter.

In a preferred embodiment of the invention the measured parameters of the QC sample are used to modify spectra of standard blood samples corresponding to either of the QC levels 1-4.

In Fig. 7 the figures in columns 2-7 of each row define
25 a standard blood sample composition, and column 1 shows
the related QC level. For each of the four standard
blood samples a corresponding standard blood spectrum
as shown in Fig. 8 may be derived mathematically by the
processor in the oximeter from predetermined spectra of
each blood component comprised in the standard blood
samples. The predetermined spectra of each blood component are, preferably, stored in the memory of the oximeter during manufacture.

Each blood component parameter value in the table in Fig. 7 has an attached plus/minus limit value. The limit values are calculated errors, which would be produced by a measurement of parameter values in the standard blood sample with an eximeter having a wavelength shift of plus and minus 0.05 nm, respectively, as the only measurement error. For example, the value of blood component FCOHb in a level 1 sample would be measured to 5.34 % or 6.66 % instead of the correct value of 6.00 %. Thus, even very small wavelength shifts in the eximeter, introduces significant errors in the measured blood parameter values, thereby illustrating the importance of quality controlling the eximeter for wavelength shifts.

(

By determining the modifications to the mathematically derived standard blood spectrum related to the level of the actual QC sample under test resulting from the parameters Δλ, c_{est} and optionally also Q_{sat}, determined in the QC procedure, the oximeter may use the modified spectrum to calculate corresponding blood parameter values. The parameter values are reported to the operator of the oximeter, and the operator may compare them with assigned control limits for the actual QC level. The effect of the instument errors revealed in the QC procedure on values reported for a blood sample with unknown blood parameter values may, e.g., appear from the deviations between the reported parameter values and the values of the relevant standard blood sample of Fig. 7.

Fig. 8 shows absorption spectra for each of standard blood sample, which absorption spectra are used in the oximeter for quality control levels 1-4. The spectra corresponding to levels 1-4 are 120, 121, 122, 123, re-

spectively. Each spectrum has a corresponding c_{ref} value corresponding to a Sulforhodamine B concentration.

The above modification to the standard blood spectra shown in Fig. 8 resulting from the parameter $\Delta\lambda$ is a shift along the wavelength axis corresponding to the difference between $\Delta\lambda$ and $\Delta\lambda_{qc}$, $\Delta\lambda_{qc}$ being either an assigned value or a predetermined fixed value stored in the memory of the oximeter. The modification of the standard blood spectra resulting from the parameter cest is a modification of the individual absorbances with the ratio c_{est}/c_{ref} .

By adopting this method of converting determined measurement errors introduced by the eximeter into parameter values of blood samples, instrument errors are reported in terms which are easily understood by the operator of the eximeter.

By noting which of the blood parameters failed the control, it may be possible to determine which of the measured parameters Δλ, c_{est} and Q_{est} caused the quality control to fail, and thereby determine which part of the oximeter that needs repair or service.

25

30

Ĺ

The relation between blood parameters that failed the quality control by being outside their corresponding control limits and the measured values of parameters $\Delta\lambda$, c_{est} , and Q_{est} and thereby an error diagnosis of the oximeter may, preferably, be comprised in a service manual for a repair technician.

According to a preferred embodiment of the invention a method is provided for repressing absorption spectra of one or several interfering components or substances

contained in a blood sample in the oximeter. Pr ferably, the oximater is adapted to repress the spectrum of Fetal Hemoglobin, which is known to cause significant interference in oximetry measurements.

5

10

In a determined blood sample spectrum, the absorbance $A_{\mathbf{a}}(\lambda)$ recorded at each wavelength λ contains contributions from each component in the sample. Interfering components are naturally treated as the other components. The magnitude of the contribution and thereby the concentration of each component in the sample is determined according to equation (18)

 $C_{V} = \mathbf{R}_{V}(\lambda) \bullet \mathbf{A}_{m}(\lambda)$.

15

The vectors $\mathbf{K}_{\mathbf{y}}(\lambda)$ are predetermined and stored in the memory of the spectrophotometer.

20

By including a Fetal Hemoglobin component in a blood sample, of which the reference spectrum is to be determined, a vector $\mathbf{K}_{\text{fotal}}(\lambda)$ corresponding to the concentration of Fetal Hemoglobin in the sample, is determined.

Preferably, the oximeter further provides a predeter-25 mined vector $\mathbf{A}_{\text{fetal}}(\lambda)$, representing the difference spectrum between Adult Hemoglobin and Fetal Hemoglobin. The vector $\mathbf{A}_{\text{fetal}}(\lambda)$ is, preferably, determined at a reference concentration cretal of 1 mmol/L.

30

The effect on determined blood parameter values due to the presence of Fetal Hemoglobin in the blood sample, is minimised by repressing the spectrum of Fetal Hemoglobin.

35

The first stage in the repression process comprises the determination of the concentration of Fetal Hemoglobin in the blood sample, according to equation (19)

5 $c_{\text{fetal}} = K_{\text{fetal}}(\lambda) \cdot A_{m}(\lambda)$.

15

ţ

The second stage comprises the determination of a modified spectrum by subtracting the difference spectrum at the determined concentration from the measured spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ of the blood sample, if $\mathbf{c}_{\text{fetal}}$ is greater than a predetermined threshold value, according to equation (20)

$$\mathbf{A}_{\text{mod}}(\lambda) = \mathbf{A}_{\mathbf{a}}(\lambda) - \frac{C_{\text{fotel}}}{1} \mathbf{A}_{\text{fotel}}(\lambda)$$

wherein $\mathbf{A}_{mod}(\lambda)$ is the modified spectrum and $c_{ref}=1$ mmol/L.

If c_{fetal} is smaller than the predetermined threshold value the modified spectrum is set equal to the measured spectrum $\mathbf{A}_{\mathbf{n}}(\lambda)$.

The third stage comprises the determination of concentrations of blood components c_y from the modified spectrum $A_{mod}(\lambda)$, whereby the effect of Fetal Hemoglobin in the blood sample on determined concentrations c_y of blood components is minimised.

By repressing the spectrum of Fetal Hemoglobin automatically, an oximeter is provided with an increased precision in measured blood parameter values, and an easier operation than currently available instruments.

According to a preferred embodiment of the invention, Fig. 9 is a graph of a variable F_{neom} plott d against

the wavelength of light striking two photodiodes in wavelength channels 70 and 71 of the photodiode array 83 in the spectrometer 1 shown in Fig. 3. The spectrometer 1 comprises a neon glow lamp (not shown), which emits at least one spectral line at a nightly accurate reference wavelength of 585.25 nm, suitably positioned within the preferred wavelength range from 480 to 670 nm. The accurate wavelength of the emitted spectral line is used in the oximeter as a reference wavelength against which the location of the 128 wavelength channels of the array 83 is adjusted. To utilise the reference wavelength a variable Fneon is defined as

 $F_{neon} = R(70)/R(71)$

(32)

15

10

5

wherein R(70) and R(71) are the magnitudes of the current or the response in each of the photodiodes located in channels 70 and 71. F_{mean} is also equal to the ratio between the light intensity striking photodiodes in channels 70 and 71, due to the linear relationship be-20 tween the current in a photodiode and the light intensity which strikes it. For example, if $F_{neon} = 1$ the light intensity striking diode 70 is equal to the light intensity striking diode 71, which means that the ref-25 erence wavelength is positioned exactly between the channels 70 and 71. Freen is used as a variable that defines the position of the light of the reference wavelength emitted from the neon lamp relative to the wavelength channels in the spectrometer 1. This characteristic of F_{neon} is utilised during field operation of the 30 oximeter, where the value of F_{neon} is measured at predetermined time intervals, and compared with a reference value F_{cal} stored in the memory of the oximeter during manufacture.

The spectrometer 1 is scanned with light emitted from a high precision monochromator in the wavelength range 585.25 +/- 7.5 nm during manufacture. A response curve for the photodiode located in channel 71 is measured. An example of a measured response curve is 131 shown in Fig. 10. A calibration algorithm comprised in the memory of the oximeter calculates a corresponding response curve for channel 70 by shifting the wavelength axis. The calibration algorithm further calculates a wavelength calibration table comprising values of the vari-10 able F_{neon} and the corresponding value of the wavelength of light emitted from the monochromator by using the determined response curves of channels 70 and 71. The oximeter stores determined values of the wavelength calibration table in the memory. A reference value of 15 F_{neon} , denoted F_{col} , is determined during manufacture by activating the neon lamp and measuring the response of channels 70 and 71, as previously described. The reference value of Fcal is stored in the memory of the oxime-20 ter.

The data comprised in the wavelength calibration table may be displayed graphically as shown in Fig. 9.

(

A calibration program measures the current temperature of the spectrometer 1 between two blood sample measurements in normal operation of the oximeter. The cuvette is always cleaned with a transparent rinse solution between two blood sample measurements. The current measured temperature of the spectrometer 1 is compared with a previous temperature measurement which was performed at the time of the previous neon lamp activation and stored in the memory of the oximeter. The calibration program determines whether the current temperature value deviates more than 0.3 °C from the previous tem-

perature value, and performs a measurement of the current value of F_{neon} if this is the case.

The graph in Fig. 9 is now used to illustrate how a 5 wavelength shift of the oximeter is determined and compensated during a period of time between two blood sample measurements, wherein the cuvette is rinsed. A first value of Fneon denoted Fcal corresponding to a first value of the wavelength denoted λ_{cal} are shown in 10 the graph, and the value of F_{cal} is determined, as previously described. A second value of the variable Fneon denoted F_{act} may be measured by the oximeter between two blood sample measurements. By utilising the predetermined wavelength calibration table comprised in the 15 memory of the oximeter a second value of wavelength λ denoted λ_{act} corresponding to F_{act} may be determined. The value of λ_{ect} may be determined from the discrete values of the variable λ comprised in the calibration table according to well-known mathematical interpolation 20 methods such as linear interpolation, polynomial interpolation, cubic spline interpolation, etc.

(

Ĺ

A wavelength shift $\Delta\lambda$ of the spectrometer may be determined from the difference between the determined value λ_{act} and the calibration value λ_{cal} . The determined wavelength shift $\Delta\lambda$ of the spectrometer 1 may be utilised to compensate a measured absorption spectrum $\lambda_{ac}(\lambda)$ of a fluid sample by determining a modified absorption spectrum $\lambda_{acd}(\lambda)$ of the sample, wherein the effect of the determined wavelength shift $\Delta\lambda$ on absorbances in the measured spectrum $\lambda_{ac}(\lambda)$ is removed.

The modified spectrum is, preferably, determined by first utilising a cubic spline function to generate interpolated absorbance values between the discrete val-

ues at the 128 wavelengths in the measured spectrum $\mathbf{A}_{m}(\lambda)$. The modified spectrum $\mathbf{A}_{modi}(\lambda)$ is determined by shifting the wavelength of each measured absorbance value in $\mathbf{A}_{m}(\lambda)$ sequentially with an amount equal to $\Delta\lambda$ and determine a corresponding interpolated absorbance value for the modified spectrum.

5

(

The provision of a spectral lamp, preferably a neon lamp, having at least one spectral line within a desired wavelength range enables the oximeter to perform 10 highly accurate measurements of the wavelengths of light absorbed by a sample by comparing the determined wavelength of said at least one spectral line with the assigned wavelength of the spectral line stored in the memory of the oximeter, calculating the possible wave-15 length shift, and compensating the determined absorbance of the sample for said wavelength shift. Accordingly, the determined absorption spectrum by the spectrometer 1 is being compensated for wavelength shifts resulting from manufacturing tolerances and temperature 20 drift during the use of the oximeter, thereby providing accurate measurements of blood parameter values.

Fig. 10 shows three response curves 130, 131 and 132 of photodiodes located in the corresponding wavelength channels 70, 71 and 72. The x-axis of the graph is the wavelength in nm of the light striking the diodes, and the y-axis of the graph is counts. The wavelength distance between the peak points of e.g. response curve 130, 131 is approximately 1.5 nm, which is the channel distance between all the 128 adjacent wavelength channels of the diode array 13.

CLAIMS

 A quality control method for a spectrophotometer, comprising the steps of:

5

10

Ĺ

determining with the spectrophotometer an absorption spectrum $A_{\alpha}(\lambda)$ of a fluid quality control sample containing a dye selected from such dyes which provide the quality control sample with an absorption spectrum with a significant absorbance peak showing a steep flank, and

determining a wavelength shift $\Delta\lambda$ between the absorption spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ of the actually measured quality control sample and a reference absorption spectrum $\mathbf{A}_{\mathbf{0}}(\lambda)$ of a reference quality control sample containing the dye stored in a memory of the spectrophotometer.

- 20 2. A method according to claim 1, wherein the wavelength shift $\Delta\lambda$ is determined from $\mathbf{A}_{\mathbf{m}}(\lambda)$ and a predetermined mathematical parameter stored in the memory of the spectrophotometer.
- 25 3. A method according to claim 2, wherein the mathematical parameter is a coefficient vector $\mathbf{C}_{\Delta\lambda}(\lambda)$ and wherein the wavelength shift $\Delta\lambda$ is determined from $\mathbf{C}_{\Delta\lambda}(\lambda) = \mathbf{A}_{\mathbf{a}}(\lambda)$.
- 30 4. A method according to claim 3, wherein the vector $C_{\Delta L}(\lambda)$ fulfils the equation

 $\Delta \lambda = C_{\Delta \lambda}(\lambda) \bullet A_{m}(\lambda)$

- 5. A method according to claim 4, wherein $C_{\lambda\lambda}(\lambda)$ has been determined from a Taylor series of the reference absorption spectrum $\lambda_0(\lambda)$.
- 5 6. A method according to claim 5, wherein $C_{\lambda \lambda}(\lambda)$ has been determined from a combination of the reference absorption spectrum $A_0(\lambda)$ and a first derivative $A_0'(\lambda)$ of said reference absorption spectrum.
- 7. A method according to any of the preceding claims 1-6, wherein the wavelength shift $\Delta\lambda$ is determined after normalisation of the determined spectrum $\mathbf{A}_n(\lambda)$ with an estimate of the concentration of the dye.

8. A method according to any of the preceding claims 1-7, wherein the quality control sample has an assigned wavelength shift $\Delta\lambda_{qc}$, which method further comprises the step of comparing $\Delta\lambda$ with $\Delta\lambda_{qc}$.

A method according to any of the preceding claims 1-8, wherein the quality control sample has a known dye concentration cqc and the dye comprises a first and a second component, the method further comprising the steps of

calculating parameters s_1 and s_2 from

$$s_1 = C_1(\lambda) \cdot A_m(\lambda)$$

30 $s_2 = C_2(\lambda) \bullet A_m(\lambda)$

15

20

in which $C_1(\lambda)$ and $C_2(\lambda)$ are predetermined vectors previously stored in the memory of the spectrophotometer, and

calculating an estimated concentration c_{est} of the dya from

 $S \qquad C_{est} = a S_1 + b S_2$

in which a and b are predetermined constants previously stored in the memory of the spectrophotometer.

10

- 10. A method according to claim 9, further comprising the step of comparing c_{est} with c_{sc} .
- 11. A method according to claims 9 or 10, further comprising the step of calculating a variable $Q_{ext} = s_2/s_1$.
- 12. A method according to any of claims 9-11, wherein the quality control sample has an assigned value of $Q_{qc} = s_2/s_1$, which method further comprises the step of comparing Q_{est} with Q_{qc} .
- 13. A method according to any of the preceding claims 1-12, wherein the spectrophotometer is an oximeter.
 - 14. A method according to claim 13, wherein spectra are measured in the wavelength range from 400 to 800 nm.

30

١

15. A method according to claims 13 or 14, further comprising the step of determining estimated errors in blood parameter values reported by the oximeter caused by the wavelength shift Δλ, option-

ally corrected by the assigned wavelength shift $\Delta\lambda_{\rm qc}.$

- 16. A method according to any of the preceding claims 13-15, further comprising the step of determining estimated errors in blood parameter values reported by the oximeter caused by a difference between cest and cqc.
- 10 17. A method according to any of the preceding claims 13-16, further comprising the step of determining estimated errors in blood parameter values reported by the oximeter caused by a difference between $Q_{\rm est}$ and $Q_{\rm qc}$.

18. A method according to any of the preceding claims 1-17 further comprising the steps of:

- determining a first reference absorption spectrum

 Aux(λ) of a reference sample containing a dye in a first concentration with a reference spectrophotometer,
- determining a first derivative $A_{01}^{\,\prime}(\lambda)$ of the first reference spectrum, and

determining from at least the first reference spectrum ${\bf A}_{01}(\lambda)$ and the first derivative ${\bf A}_{01}^{-1}(\lambda)$ a mathematical parameter from which a wavelength shift $\Delta\lambda$ of the spectrophotometer can be determined, and

storing the mathematical parameter in a memory of the spectrophotometer.

35

15

- 19. A method according to claim 18, wherein the step of determining the mathematical parameter comprises the steps of
- 5 calculating a set of calibration vectors $\mathbf{B_i}(\lambda)$ according to

$$\mathbf{B}_{i}(\lambda) = \mathbf{S}_{i}\mathbf{A}_{01}(\lambda) + \mathbf{S}_{i}\mathbf{A}_{01}(\lambda)$$

- in which i = 1, 2, ..., N (N>1) and s_i are constants of selected values,
- determining a coefficient vector $\mathbf{C}_{\Delta \lambda}(\lambda)$ constituting the mathematical parameter so that each set of corresponding values \mathbf{s}_{i3} , \mathbf{B}_i satisfies:

$$s_{i3} = C_{\Delta\lambda}(\lambda) \cdot B_i(\lambda), \quad i = 1, 2, ..., N$$

20. A method according to claim 18, wherein the dye comprises a first component and a second component, and further comprising the step of determining a second reference spectrum λ₀₂(λ) of a second reference sample containing the dye in a second concentration with the reference spectrophotometer, and wherein the step of determining a mathematical parameter comprises the steps of

calculating a set of vectors $\mathbf{B_i}(\lambda)$ from

30
$$B_i(\lambda) = S_{i1} A_1(\lambda) + S_{i2} A_2(\lambda) + S_{i3} A_0'(\lambda)$$

ţ

in which $\mathbf{A}_1(\lambda)$ and $\mathbf{A}_2(\lambda)$ are derived from the first and second reference spectra $\mathbf{A}_{01}(\lambda)$, $\mathbf{A}_{02}(\lambda)$ and represent spectral information about the first and second components, respectively, and

i=1,2,...,N, and s_{i1} , s_{i2} and s_{i3} are constants of selected values,

determining a vector $\mathbf{C}_{\Delta L}(\lambda)$ constituting the mathematical parameter so that

 $s_{i3} = C_{i\lambda}(\lambda) \cdot B_{i}(\lambda)$

- 21. A spectrophotometer comprising a processor that is adapted to determine the wavelength shift Δλ between an absorption spectrum A_m(λ) determined with the spectrophotometer on a fluid quality control sample containing a dye selected from such dyes which provide the quality control sample with an absorption spectrum with a significant absorbance peak showing a steep flank and a reference absorption spectrum A_Q(λ) of a reference quality control sample containing the dye, stored in the memory of the spectrophotometer.
- 22. A spectrophotometer according to claim 21, wherein the wavelength shift $\Delta\lambda$ is determined from $\mathbf{A}_{\mathbf{a}}(\lambda)$ and a predetermined mathematical parameter stored in the memory of the spectrophotometer.
 - 23. A spectrophotometer according to claim 22, wherein the mathematical parameter is a coefficient vector $C_{\Delta \lambda}(\lambda)$ and wherein the wavelength shift $\Delta \lambda$ is determined from $C_{\Delta \lambda}(\lambda) \bullet A_{\Delta}(\lambda)$.
 - 24. A spectrophotometer according to claim 23, wherein the vector $\mathbf{C}_{\Delta}(\lambda)$ fulfils the equation
- $\Delta \lambda = C_{A\lambda}(\lambda) \bullet A_{\alpha}(\lambda)$

30

- 25. A spectrophotometer according to claim 24, wherein $C_{\Delta\lambda}(\lambda)$ has been determined from a Taylor series of the reference absorption spectrum $A_0(\lambda)$.
- 5 26. A spectrophotometer according to claim 25, wherein $C_{0\lambda}(\lambda)$ has been determined from a combination of the reference absorption spectrum $A_0(\lambda)$ and a first derivative $A_0'(\lambda)$ of said reference absorption spectrum.
- 27. A spectrophotometer according to any of the preceding claims 21-26, wherein the wavelength shift $\Delta\lambda$ is determined after normalisation of the determined spectrum $\mathbf{A}_{\mathbf{a}}(\lambda)$ with an estimate of the concentration of the dye.
 - 28. A spectrophotometer according to any of the preceding claims 21-27, wherein the quality control sample has an assigned wavelength shift $\Delta\lambda_{qc}$, and wherein the processor is adapted to compare $\Delta\lambda$ with $\Delta\lambda_{qc}$.
- 29. A spectrophotometer according to any of the preceding claims 21-28, wherein the quality control sample has a known dye concentration cqc and the dye comprises a first and a second component, and wherein the processor is adapted to

calculate parameters s_1 and s_2 from

 $s_1 = C_1(\lambda) \bullet A_{\alpha}(\lambda)$

10

20

30

ţ

 $S_2 = C_2(\lambda) \bullet A_m(\lambda)$

AMENDED SHEET

in which $C_1(\lambda)$ and $C_2(\lambda)$ are predetermined vectors previously stored in the memory of the spectrophotomater, and

5 calculate an estimated concentration cest of the dye from

$C_{est} = a s_1 + b s_2$

(

- in which a and b are predatermined constants previously stored in the memory of the spectrophotometer.
- 30. A spectrophotometer according to claim 29, wherein the processor is further adapted to compare $c_{\rm est}$ with $c_{\rm qc}$.
- 31. A spectrophotometer according to claims 29 or 30, wherein the processor is further adapted to calculate a variable $Q_{est} = s_2/s_1$.
- 32. A spectrophotometer according to any of claims 29-31, wherein the quality control sample has an assigned value of $Q_{qc} = s_2/s_1$ and wherein the processor is further adapted to compare Q_{est} with Q_{qc} .
 - 33. A spectrophotometer according to any of the preceding claims 21-32 which is an oximeter.
- 30 34. A spectrophotometer according to claim 33, wherein spectra are measured in the wavelength range from 400 to 800 nm.
- 35. A spectrophotometer according to claims 33 or 34, wherein the processor is adapted to determine es-

timated errors in blood parameter values reported by the spectrophotometer caused by the wavelength shift $\Delta\lambda$, optionally corrected by the assigned wavelength shift $\Delta\lambda_{qr}$.

5

10

Ĺ

- 36. A spectrophotometer according to any of the preceding claims 33-35, wherein the processor is further adapted to determine estimated errors in blood parameter values reported by the spectrophotometer caused by a difference between cest and cqc.
- 37. A spectrophotometer according to any of the preceding claims 33-36, wherein the processor is further adapted to determine estimated errors in blood parameter values reported by the spectrophotometer caused by a difference between $Q_{\rm est}$ and $Q_{\rm qc}$.
- 20 38. A spectrophotometer according to any of the preceding claims 21-37 for the determination of a concentration c_y of a component y of a sample and wherein the memory further comprises
- at least one vector $\mathbf{A}_{\text{lat}}(\lambda)$ representing spectral information of an interfering component in the sample at a concentration c_{ref} , and
- at least one predetermined vector $\mathbf{K}_{int}(\lambda)$, and wherein

the processor is further adapted to

calculate the concentration c_{ist} of the interfering component according to

 $C_{int} = K_{int}(\lambda) \cdot A_{n}(\lambda)$, and

if c_{int} is greater than a predetermined threshold value, c_{ref} , calculate a modified absorbance spectrum $R_{mod}(\lambda)$ according to

$$\mathbf{A}_{\text{sod}}(\lambda) = \mathbf{A}_{n}(\lambda) - \frac{\mathbf{C}_{\text{int}}}{\mathbf{C}_{\text{ref}}} \mathbf{A}_{\text{int}}(\lambda)$$
, and

determine c_y from the modified spectrum $A_{mod}(\lambda)$ according to

$$c_{y} = K_{y}(\lambda) \bullet A_{mod}(\lambda)$$

5

- where $\mathbf{K}_{\mathbf{y}}(\lambda)$ is a predetermined vector and whereby the effect of interfering components on determined concentrations $\mathbf{c}_{\mathbf{y}}$ is minimised.
- 39. A spectrophotometer according to claim 38, wherein the interfering component is fetal hemoglobin.
- 40. A spectrophotometer according to any of the preceding claims 21-39 further comprising a spectral lamp for emission of light with at least one spec-25 tral line, and a processor, including a memory, that is adapted to determine the wavelength of the at least one spectral line and to compare the determined wavelength of said at least one spectral line with the assigned wavelength from an initial 30 calibration procedure of said spectral line stored in the memory of the spectrophotometer, calculate a wavelength shift, and compensate the determined absorption spectrum of said sample for said wavel ngth shift.

- 41. A spectrophotometer according to claim 40, which is an eximeter, and wherein the spectral lamp emits light with at least one spectral line in the wavelength range 480-670 nm, and said eximeter is further provided with at least two photodiodes each of which convert the emitted light from the spectral lamp into a current substantially proportional to the light intensity which strikes the photodiode, and wherein the processor of said eximeter calculates the ratio Fnees between the two photodiods currents.
- 42. A spectrophotometer according to claim 41, wherein said spectral lamp is a neon lamp which is activated when the temperature of the spectrometer deviates more than a critical temperature difference, such as more than about 0.2-0.5°C from the previous Fmeon measurement.

5

10



r ATENT COOPERATION TREATY

To:

From the	INTERNATIONAL	BUREAU
----------	---------------	--------

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

Assistant Commissioner for Patents United States Patent and Trademark

Office Box PCT

Washington, D.C.20231 ÉTATS-UNIS D'AMÉRIQUE

11 February 2000 (11.02.00)	in its capacity as elected Office				
International application No. PCT/DK99/00313	Applicant's or agent's file reference P221WO				
International filing date (day/month/year) 10 June 1999 (10.06.99)	Priority date (day/month/year) 12 June 1998 (12.06.98)				

Applicant

HANSEN, Heine

1.	The designated Office is hereby notified of its election made:			
	X in the demand filed with the International Preliminary Examining Authority on:	,	· ·	
	11 December 1999 (11.12.99)	• • •		
	in a notice effecting later election filed with the International Bureau on:		•	
		•		
2.	The election X was			
	was not			
	made before the expiration of 19 months from the priority date or, where Rule 32 app Rule 32.2(b).	lies, within the tim	e limit under	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35

Authorized officer

F. Baechler

Telephone No.: (41-22) 338.83.38

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/DK99/00313

i. Dasis di tile lepui	I.	Basis	of the	repor
------------------------	----	-------	--------	-------

1. This report has been drawn on the basis of (substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):
Description, pages:

	Des	scription, pages:				
	1-4	2	as received on	14/09/2000	with letter of	14/09/2000
	Cla	ims, No.:				
	1-4	2	as received on	14/09/2000	with letter of	14/09/2000
	Dra	wings, sheets:				
	1/9-	-9/9	as originally filed			
2.	The	amendments have	e resulted in the cancellation of:			
		the description,	pages:			
		the claims,	Nos.:			
		the drawings,	sheets:			
3.		This report has be considered to go be	een established as if (some of) the peyond the disclosure as filed (F	e amendmen Rule 70.2(c)):	ts had not been made,	since they have been

4. Additional observations, if necessary:

see separate sheet

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/DK99/00313

V. R asoned statem int under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes:

Claims 1-42

No:

Claims

Inventive step (IS)

Yes: Claims 1-42

No:

Claims

Industrial applicability (IA)

Yes:

Claims 1-42

No: Claims

2. Citations and explanations

s e separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

EXAMINATION REPORT - SEPARATE SHEET

Re Item I

Basis of the opinion

(The application does not appear to involve extension beyond the originally filed disclosure, for the following reasons).

Amended claim 1 seems to be based in its wording to a large extent on originally filed claim 1, with (i) an additional feature concerning the steep flank of the absorbance peak, (ii) a reference to a reference absorption spectrum $A_o(\lambda)$. The feature determining this wavelength shift from $C_{\Delta\lambda}(\lambda)$. $A_m(\lambda)$ has been omitted, being relegated to claim 3.

As far as can be seen, amendments (i) and (ii) are based on the original disclosure (i) at page 13, lines 3-5, and claim 5, and (ii) various references throughout the description concerning the wavelength shift of the absorption spectrum with respect to a reference spectrum of a reference sample containing the dye. Thus these amendments to claim 1 can be considered to be a mere limitations in scope.

The omission of feature comprising the formula can be considered NOT to represent an extension beyond the original disclosure, since original claim 18 although not a method claim, defined a concept which referred generally to a mathematical parameter and was not restricted to the parameter including the predetermined coefficient vector. This appeared in dependent claim 19, indicating it was a preferred calculation possibility to determine the wavelength shift. It is reasonable to imagine a method of equivalent scope to original claim 18, and this would have been of broader scope than original claim 1, so providing a support for the present broadening of claim 1.

Claim 21 would also appear not to represent an extension. Likewise the dependent claims seem to be substantially based on the originally field claims, except for claims 5 and 25, which seem to be based on page 6, line 14.

Re Item V

Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

The invention relates to a method of quality control checking of spectrophotometer... and a spectrophotometer arranged for such checking.

Object of the invention is to improve such quality control checking...

Solution provided by the invention is as defined in claims 1 and 21, involving determining the wavelength shift of an actually measured spectrum of a quality control sample compared with a reference spectrum of said sample stored in the processor of the spectrophotometer.

Prior art documents:

D1...WO-A-9630742 deals with comparison between a current spectrum measurement and a reference one, stored in the instrument (see e.g. page 2, lines 10-25 of D1), but this involves a fitting technique which depends on intensity differences, more than a wavelength shift.

D2...WO-A-9408225 involves using one spectrophotometer to calibrate another.

D3...US-A-5592291 relates to a correction method for a spectrophotometer involving reading out data from a memory and correcting data for a target point in three dimensional space.

D4...EP-A-0167816 describes the use of operational amplifiers to correct blood monitoring information.

None of the documents disclose or seem to hint at the claimed method and apparatus.

Re Item VIII

Certain observations on the international application

Lack of clarity:

a. In claim 18, which according to the applicant relates to steps performed before those of claim 1, the references to "the spectrophotometer" at lines 30 and 34, might be mistakenly taken to refer to the "reference spectrophotometer", when they apparently refer to the spectrophotometer of claim 1. The claim should have been clarified in this respect.

Also page 9, lines 5-10 should have been corrected in this respect.

b. The passage page 7, lines 5-14, seems to repeat features which are already in the statement on page 6 corresponding to claim 1.



REQUEST

For receiving Office use only
International Application No.
International Filing Date

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.	Name of receiving Office	and "PCT International Application"						
	Applicant's or agent's file reference (if desired) (12 characters maximum) P221WO							
Box No. I TITLE OF INVENTION								
A method in quality control of a spect	rophotometer							
Box No. II APPLICANT								
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)								
Radiometer Medical A/S		Telephone No. +45 38 27 38 27						
Aakandevej 21								
DK-2700 Broenshoej Denmark		Facsimile No. +45 ³⁸ 27 . ²⁷ . 27						
		Teleprinter No. 15411						
State (that is, country) of nationality:	State (that is, country) o							
DK		DK						
This person is applicant all designated for the purposes of:		America only the States indicated in the Supplemental Box						
Box No. III FURTHER APPLICANT(S) AND/OR (FURTH								
Name and address: (Family name followed by given name: for a designation. The address must include postal code and name of counaddress indicated in this Box is the applicant's State (that is, country of residence is indicated below.) HANSEN, Heine Jættevej 4 3650 Ølstykke Denmark	legal entity, full official ntry. The country of the) of residence if no State	This person is: X applicant only applicant and inventor inventor only (If this check-box is marked, do not fill in below.)						
State (that is, country) of nationality:	State (that is, country) o							
DK		DK						
This person is applicant all designated all designated for the purposes of:		United States the States indicated in the Supplemental Box						
Further applicants and/or (further) inventors are indicated of	on a continuation sheet.							
Box No. IV AGENT OR COMMON REPRESENTATIVE	OR ADDRESS FOR CO	PRRESPONDENCE						
The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:								
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)								
Radiometer Medical A/S		+45 38 27 38 27						
Patent Department		Facsimile No.						
Aakandevej 21		+45 38 27 27 27						
DK-2700 Broenshoej Denmark		Teleprinter No.						
Definition		15411						
Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.								

			2	!	
Sheet	No.				

Box N	lo.V	DESIGNATION F STATES							
The f	ollow	ing designations are hereby made under Rule 4.9(a) (n	nark th	ne applicable check-boxes; at least one must be marked):				
Regional Patent									
		ARIPO Patent: GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT							
	EA	Eurasian Patent: AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State							
[2]	EP	of the Eurasian Patent Convention and of the PCT European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany,							
_		DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT							
	OA	OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Maii, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)							
N1									
Nauor		tent (if other kind of protection or treatment desired, special	y on						
		Albania		LS	Lesotho				
	AM	Armenia		LT	Lithuania				
	ΑT	Austria		LU	Luxembourg				
	ΑU	Australia		LV	Latvia				
\Box		Azerbaijan		MD	Republic of Moldova				
=		Bosnia and Herzegovina			Madagascar				
		-	=		_				
		Barbados		MIN	The former Yugoslav Republic of Macedonia				
		Bulgaria			•••••				
	BR	Brazil		MN	Mongolia				
	BY	Belarus		MW	Malawi				
	CA	Canada		MX	Mexico				
		and LI Switzerland and Liechtenstein	$\overline{\Box}$	NO	Norway				
		China			New Zealand				
			=						
		Cuba		PL	Poland				
		Czech Republic		PT	Portugal				
	DE	Germany	Ш	RO	Romania				
	DK	Denmark		RU	Russian Federation				
	EE	Estonia		SD	Sudan				
	ES	Spain		SE	Sweden				
	FI	Finland		SG	Singapore				
$\bar{\Box}$	GB	United Kingdom		SI	Slovenia				
		Grenada		SK	Slovakia				
		Georgia		SL	Sierra Leone				
		<u> </u>							
		Ghana			Tajikistan				
므		Gambia			Turkmenistan				
Ш		Croatia		TR	•				
	HU	Hungary		TT	Trinidad and Tobago				
	ID	Indonesia		UA	Ukraine				
	IL	Israel		UG	Uganda				
	IN	India	X	US	United States of America				
	IS	Iceland	_						
X	JP	Japan		117	Uzbekistan				
_			=		Viet Nam				
		Kenya							
l Li		Kyrgyzstan			Yugoslavia				
	KP	Democratic People's Republic of Korea		ZW	Zimbabwe				
			Che	ck-bo	xes reserved for designating States (for the purposes of				
	KR	Republic of Korea	a na	itional	I patent) which have become party to the PCT after				
	KZ	Kazakhstan	เรรน	ance (of this sheet:				
	LC	Saint Lucia							
		Sri Lanka	$\overline{\Box}$						
		Liberia	Ħ						
'n					shove the applicant also makes under Dule 4 9(h) all other				

Precautionary Designation Statement: In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation fees. Confirmation must reach the receiving Office within the 15-month time limit.)

Sheet No. ... Box No. VI PRIORITY CL Further prior laims are indicated in the Supplemental Box. Number Filing date Where earlier application is: of earlier application of earlier application national application: regional application:* international application: (day/month/year) regional Office country receiving Office item(1) 12 June 1998 (12/06/98)1998-00783 DK item (2) item (3) The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s). • Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box. INTERNATIONAL SEARCHING AUTHORITY Choice of International Searching Authority (ISA) Request to use results of earlier search; reference to that search (if an earlier (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used): search has been carried out by or requested from the International Searching Authority). Number Date (day/month/year) Country (or regional Office) ISA / SE Box No. VIII CHECK LIST; LANGUAGE OF FILING This international application contains This international application is accompanied by the item(s) marked below: the following number of sheets: 1. A fee calculation sheet request 2. separate signed power of attorney description (excluding 41 3. copy of general power of attorney; reference number, if any: sequence listing part) claims 8 4. statement explaining lack of signature abstract 1 5. priority document(s) identified in Box No. VI as item(s): 9 drawings 6. translation of international application into (language): sequence listing part 7. separate indications concerning deposited microorganism or other biological material 0 of description 8.

nucleotide and/or amino acid sequence listing in computer readable form Search Report DK 1998-00783 62 9. \times other (specify): Total number of sheets: Figure of the drawings which Language of filing of the 8 English should accompany the abstract: international application: SIGNATURE OF APPLICANT OR AGENT Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request). RADIOMETER MEDICAL A/S Hein Hann Yeu M Mour Lene Meineche Marnæs Patent Department

		For receiving Office use only	
1.	Date of actual receipt of the purported international application:		2. Drawings:
3.	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:	received:	
4.	Date of timely receipt of the required corrections under PCT Article 11(2):		not received:
5.	International Searching Authority (if two or more are competent): ISA /	6. Transmittal of search copy delayed until search fee is paid.	

For International Bureau use only

Date of receipt of the record copy by the International Bureau:



PCT

NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To:

RADIOMETER MEDICAL A/S Patent Dept. Aakandevej 21 DK-2700 Broenshoej DANEMARK

II.	MPORTANT NOTICE
	Priority date (day/month/year) 12 June 1998 (12.06.98)
	filing date (day/month/year) e 1999 (10.06.99)

 Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice: EP,JP,US

in accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

None

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

 Enclosed with this Notice is a copy of the international application as published by the International Bureau on 23 December 1999 (23.12.99) under No. WO 99/66310

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a **demand for international preliminary examination** must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the **national phase**, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

·	The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer J. Zahra
	Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

WO 99/66310 PCT/DK99/00313



NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

ate of mailing (day month-year) 23 December 1999 (23.12.99)	IMPORTANT NOTICE International application No. PCT/DK99/00313		
oplicant's or agent's file reference P221WO			
The applicant is hereby notified that, at the time of	f establishment of this Notice, the time limit under Rule 46.1 for making d the International Bureau had received neither such amendments nor a		
claration that the applicant does not wish to make	amendments.		
	•		

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/

PCT

CHAPTER II

DEMAND

under Article 31 of the Patent Cooperation Treaty.

The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty and hereby elects all eligible States (except where otherwise indicated).

For International Preliminary Examining Authority use only					
dentification of IPEA		Date of receipt of DI	EMAND		
Box No. 1 IDENTIFICATION OF T	HE INTERNATIONAL	APPLICATION	Applicant's or agent's file reference P221WO		
International application No	International filing date	(day/month/year)	(Earliest) Priority date (day/month/year)		
PCT/DK99/00313	10 June 1999	(10.06.99)	12 June 1998 (12.06.98)		
Title of invention					
A method in Quality Cont	rol of a Specti	rophotometer			
Box No. II APPLICANT(S)					
Name and address: (Family name followed by given name: for a legal entity, full official designation. The address must include postal code and name of country.) Radiometer Medical A/S Aakandevej 21 DK-2700 Broenshoej		full official designation.	Telephone No.:		
			+45 38 27 38 27		
			Facsurule No		
			+45 38 27 27 27		
Denmark		•	Teleprinter No.: 15411		
State (that is, country) of nationality:	DK	State (that is, coun	סיייי) of residence: DK		
Name and address (Family name followed by HANSEN, Heine Jættevej 4 DK-3650 Ølstykke DEnmark	grven name; jor a legal entity, fi	ull official designation. I hi	; address must include postal code and name of country.)		
State (that is, country) of nationality State		State (that is, cour	(that is, country) of residence:		
	DK		DK		
Name and address. IFamily name followed b	y given name: for a legal entity.	full official designation. Th	ne address must include postal code and name of country		
State (that is, country) of nationality		State (that is, coun.	ற, of residence		
Further applicants are indicated	on a continuation sheet.				

Sheet No 2

International application No PCT/DK99/00313

BOX NO. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR COL	RRESPONDENCE					
The following person is agent X common representative						
and X has been appointed earlier and represents the applicant(s) also for international preliminary examination						
is hereby appointed and any earlier appointment of (an) agent(s) common representative is hereby revoked.						
is hereby appointed, specifically for the procedure before the International Prelimit the agent(s) common representative appointed earlier	nary Examining Authority, in addition to					
Name and address (Family name followed by given name, for a legal entity, full official designation. The address must include postal zode and name of country.)	Telephone No.:					
Radiometer Medical A/S	+45 38 27 38 27					
Patent Department	Facsimile No.:					
Aakandevej 21	+45 38 27 27 27					
DK-2700 Broenshoej Denmark	Talandara Na					
	Teleprinter No.:					
	15411					
Address for correspondence: Mark this check-box where no agent or common re space above is used instead to indicate a special address to which correspondence	presentative is has been appointed and the should be sent.					
Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION						
Statement concerning amendments:*						
1. The applicant wishes the international preliminary examination to start on the basis of:						
the international application as originally filed						
the description as originally filed						
as amended under Article 34						
the claims as originally filed						
as amended under Article 19 (together with any accompanying	statement)					
as amended under Article 34						
the drawings as originally filed						
as amended under Article 34						
2 The applicant wishes any amendment to the claims under Article 19 to be consider	red as reversed.					
3. The applicant wishes the start of the international preliminary examination to be postponed until the expiration of 20 months from the priority date unless the International Preliminary Examining Authority receives a copy of any amendments made under Article 19 or a notice from the applicant that he does not wish to make such amendments (Rule 69.1(d)). (This check-box may be marked only where the time limit under Article 19 has not yet expired.)						
Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.						
Language for the purposes of international preliminary examination: English						
which is the language in which the international application was filed.						
which is the language of a translation furnished for the purposes of international search.						
which is the language of publication of the international application.						
which is the language of the translation (to be) furnished for the purposes of international preliminary examination.						
Box No. V ELECTION OF STATES						
The applicant hereby elects all eligible States that is, all States which have been designated and which are bound by Chapter II of						
the PCT)						
excluding the following States which the applicant wishes not to elect:						

Sheet No 3

International application No PCT/DK99/00313

Box No. VI CHECK LIST			·				
The demand is accompanied by the following elements, in the language re Box No. IV, for the purposes of international preliminary examination	For International Preliminary Examining Authority use only received not received						
l translation of international application	sheets						
2. amendments under Article 34	sheets						
copy (or, where required, translation) of amendments under Article 19	sheets						
4. copy (or, where required, translation) of statement under Article 19	sheets						
5. letter	sheets						
6. other (specify)	sheets						
The demand is also accompanied by the item(s) marked below:		- 					
1. X fee calculation sheet 4.	fee calculation sheet 4. statement explaining lack of signature						
2. separate signed power of attorney 5.	5. nucleotide and or amino acid sequence listing in computer readable form						
copy of general power of attorney. reference number, if any 6. other (specify)							
Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE							
Next to each agreement, indicate the name of the person agreen and the capacity in which the person agree of such capacity is not obvious from reading the demand). RADIOMETER MEDICAL A/S Alu: (i) Ulau: Lene Meineche Marnæs Patent Department							
For International Preliminary Evani	sing Authority	use only					
1. Date of actual receipt of DEMAND:							
Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):							
The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply. The applicant has been informed accordingly.							
4. The date of receipt of the demand is WITHEN the period of 19 months from the priority date as extended by virtue of Rule 80.5.							
Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.							
For International Bure	au use only _						
Demand received from IPEA on:							